Phase I Study to Determine the Optimal Human Challenge Dose for 
Norovirus GII.4 CIN- 3 Batch No.: 01 -16C3  
 
DMID Protocol Number:  17-0102 
DMID Funding Mechanism:  
 Other Identifying Numbers:  
IND Sponsor: NIAID 
Lead Principal Investigator:  [INVESTIGATOR_108401] W. Frenck, Jr, M.D. 
DMID Clinical Project Manager: Gabriele Malone , R.N., M.S.N. 
Draft or Version Number: 7.[ADDRESS_533746] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           2 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 STATEMENT OF ASSURANCE  
Each Institution will hold a current Federal Wide Assurance (FWA) issued by [CONTACT_12198] (OHRP) for federally -funded human subjects research. Each FWA 
will designate at least one Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) registered with OHRP, for which the research will be reviewed and approved by [CONTACT_5040]/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated under an FWA may include an institution’s IRB/IEC, an independe nt IRB/IEC, or an IRB/IEC of 
another institution after establishing a written agreement with that other institution.  
 
DMID Protocol 17-[ADDRESS_533747] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           3 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 STATEMENT OF COMPLIANCE  
The study trial  will be carried out in accordance with Good Clinical Practice (GCP) and as 
required by [CONTACT_716]: 
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46 : Protection of Human 
Subjects 
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 
(Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_1615]) , 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 
CFR Part 312  (Investigational New Drug Application), 21 CFR 812 (Investigational 
Device Exemptions) 
• International Conference on Harmonis ation : Good Clinical Practice ( ICH E6 ); 62 Federal 
Register [ZIP_CODE] (1997); and future revisions 
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects 
of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving Human Subjects, as applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , 
as applicable 
• Applicable Federal, State, and Local Regulations and Guidance 
  
DMID Protocol 17-[ADDRESS_533748] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           4 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 SIGNATURE [CONTACT_140180], including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and 
ICH E6 Good Clinical Practice (GCP) guidelines. 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when necessary to protect the safety, rights, or welfare of subjects.  
Site Investigator Signature : 
 
[INVESTIGATOR_14586]:  Date:   
 Name  
[CONTACT_422774] 17-[ADDRESS_533749] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533750] OF ABBREVIATIONS  ........................................................................................................12  
PROTOCOL SUMMARY  .............................................................................................................16  
1 KEY ROLES  ..............................................................................................................21  
2 BACKGROUND AND SCIENTIFIC RATIONALE  ................................................22  
2.1 Background .................................................................................................................22  
2.2 Scientific Rationale  .....................................................................................................24  
 Purpose of Study .........................................................................................................25  
 Study Population .........................................................................................................25  
2.3 Potential Risks and Benefits  .......................................................................................25  
 Potential Risks ............................................................................................................25  
 Potential Benefits  ........................................................................................................27  
3 STUDY DESIGN, OBJECTIVES AND ENDPOINTS OR OUTCOME 
MEASURES  ...............................................................................................................28  
3.1 Study Design Description ...........................................................................................28  
3.2 Study Objectives .........................................................................................................29  
 Primary  .......................................................................................................................29  
 Secondary ...................................................................................................................29  
 Exploratory  .................................................................................................................29  
 Future Use Samples/Assays  ........................................................................................[ADDRESS_533751] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           6 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 
 Primary  .......................................................................................................................30  
 Secondary ...................................................................................................................30  
 Exploratory  .................................................................................................................30  
4 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ...............................[ADDRESS_533752] Storage and Stability .....................................................................................34  
4.2 Acquisition/Distribution  .............................................................................................35  
4.3 Protocol- Specified Medications/Treatments other than Study Products  ....................35  
4.4 Dosage/Regimen, Preparation, Dispensing and Administration of Study 
Intervention/Investigational Product  ..........................................................................36  
4.5 Pre-determined Modification of Study Intervention/Investigational Product 
for an Individual Subject ............................................................................................37  
4.6 Accountability Procedures for the Study Intervention/Investigational Product(s) ....................................................................................................................[ADDRESS_533753] Replacement  ..................................................................................................44  
 Study Termination ......................................................................................................44  
6 STUDY PROCEDURES  ............................................................................................45  
6.1 Screening Visit 00A (Day -60 to - 2) ...........................................................................45  
 Screening Visit 00B (Day -1) .....................................................................................[ADDRESS_533754] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533755]- Challenge: Visit 02 -05 (Days 2-5) ......................................................[ADDRESS_533756] Challenge Visits  ................................................................................51  
 Visit 06, Day 6 (+2, Day 6-8) .....................................................................................51  
 Visit 07, Day 15 (+/- 1, Day 14-16).............................................................................52  
 Visit 08, Day 30 (- 2/+5, Day 28-35)...........................................................................53  
 Visit 09, Day 45 (- 5/+5, Day 40-50)...........................................................................54  
 Visit 10 Day 60 (- 5/+5, Day 55-65)............................................................................[ADDRESS_533757]  ....................................................................................................55  
6.4 Early Inpatient Discharge  ...........................................................................................55  
6.5 Transfer to acute care hospi[INVESTIGATOR_307]  ....................................................................................56  
6.6 Unscheduled Study Visits ...........................................................................................56  
6.7 Protocol Deviations ....................................................................................................56  
7 DESCRIPTION OF CLINICAL AND LABORATORY EVALUATIONS  .............58  
7.1 Clinical Evaluations  ....................................................................................................58  
7.2 Laboratory Evaluations  ...............................................................................................63  
 Laboratory Specimen Preparation, Handling, and Storage ........................................67  
 Laboratory Specimen Shippi[INVESTIGATOR_007]  ..................................................................................68  
8 ASSESSMENT OF SAFETY  .....................................................................................69  
8.1 Assessing and Recording Safety Parameters  ..............................................................69  
 Adverse Events (AEs)  .................................................................................................69  
 Solicited Adverse Events  ............................................................................................71  
 Serious Adverse Events (SAEs)  .................................................................................71  
 New-Onset Chronic Medical Conditions (NOCMCs) ................................................[ADDRESS_533758] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533759] Values or Abnormal Clinical Findings ...................................................................................76
 
8.6 Halting Rules ..............................................................................................................76  
 Study Halting Criteria  .................................................................................................76  
8.7 Safety Oversight (ISM plus SMC)  .............................................................................77  
 Independent Safety Monitor (ISM) ............................................................................77  
 Safety Monitoring Committee (SMC) ........................................................................[ADDRESS_533760]/Independent Ethics Committee  ......................................79  
9.2 Informed Consent Process ..........................................................................................79  
9.3 Consent for Future Use of Stored Specimens and Data .............................................81  
9.4 Exclusion of Women, Minorities, and Children (Special Populations) ......................[ADDRESS_533761] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           9 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 
 Interim Immunogenicity or Efficacy Review  .............................................................87  
10.5  Final Analysis Plan  .....................................................................................................87  
 Analysis Populations ..................................................................................................88  
 Primary Objectives  .....................................................................................................88  
 Secondary Objectives  .................................................................................................89  
 Exploratory Objectives  ...............................................................................................90  
 Handling Missing Data ...............................................................................................91  
11 ELECTRONIC CASE REPORT FORMS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  ...............................................................................................[ADDRESS_533762] KEEPI[INVESTIGATOR_1645] ......................................................95  
13.1  Data Management Responsibilities  ............................................................................95  
13.2  Data Coordinating Center/Biostatistician Responsibilities  ........................................95  
13.3  Data Capture Methods  ................................................................................................95  
13.4  Types of Data ..............................................................................................................96  
13.5  Study Records Retention ............................................................................................96  
14 CLINICAL MONITORING  .......................................................................................97  
15 PUBLICATION POLICY ..........................................................................................98  
16 LITERATURE REFERENCES  ..................................................................................99  
17 APPENDICES ..........................................................................................................100  
Appendix A: Schedule of Events .................................................................................................101  
Appendix B: Toxicity Table/Laboratory Adverse Event Grading Scale .....................................106  
Appendix C: Vital Signs Adverse Event Grading Scale ..............................................................107  
Appendix D: Diarrhea/Vomiting Grading Scale  ..........................................................................108  
Appendix E: Solicited Adverse Events Grading Scale ................................................................109  
Appendix F: Modified Vesikari Score .........................................................................................[ADDRESS_533763] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533764] OF TABLES  
Table 1: Venipuncture/Blood Volumes (mL) ................................................................................60  
Table 2. Saliva and Stool Collection ..............................................................................................61  
Table 3. Observed illness rates and 95% confidence intervals for a challenge dose group 
of   N=[ADDRESS_533765] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533766] OF FIGURES  
Figure 1: Schematic of Study Design ............................................................................................[ADDRESS_533767] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533768] OF ABBREVIATIONS  
AE Adverse Event  
AGE  Acute Gastroenteritis  
ALS  Antibody Lymphocyte Supernatant  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count  
APC  Antigen Presenting Cell  
ASC   Antibody -Secreting Cell  
BPM  Beats Per Minute  
BUN  Blood Urea Nitrogen  
°C Degrees Celsius  
CCHMC  Cincinnati Children’s Hospi[INVESTIGATOR_422672] 17-[ADDRESS_533769] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           13 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 EIA Enzyme Immunosorbent Assay  
ELISA  Enzyme -Linked Immunosorbent Assay  
°F Degrees Fahrenheit  
FDA  Food and Drug Administration  
FWA  Federal wide  Assurance  
GII.4  Norovirus genogroup II, genotype 4  
GCP  Good Clinical Practice  
GM-CSF  Granulocyte -Macrophage Colony Stimulating Factor  
HBGA s Histo -blood Group Antigens  
HEENT  Head, Eyes, Ears, Nose, Throat  
Hgb Hemoglobin  
HID50 Human Infectious Dose Causing 50% Infection  
HIV Human I mmunodeficiency Virus  
HRP  Horseradish Peroxidase  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICS Intracellular Cytokine Staining  
IDES  Internet Data Entry System  
IEC Independent or Institutional Ethics Committee  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IL Interleukin  
IND Investigational New Drug Application  
DMID Protocol 17-[ADDRESS_533770] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533771]  
ISM Independent Safety Monitor  
IUD Intrauterine Device  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_19737])  
NK  Natural Killer Cell  
NOCMCs New-Onset Chronic Medical Co nditions 
NoV  Norovirus  
NPO  Nothing by [CONTACT_422714] P-Particle  
QA Quality Assurance  
QC Quality Control  
qRT-PCR  Quantitative Reverse Transcriptase Polymerase Chain 
Reaction (also known as Real -time RT -PCR)  
RNA  Ribonucleic Acid  
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction  
DMID Protocol 17-[ADDRESS_533772] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533773] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           16 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 PROTOCOL SUMMARY 
Title:  Phase I Study to Determine the Optimal Human Challenge Dose for  
Norovirus GII.4 CIN- 3 Batch No.: 01-16C3 
Design of the Study:  Subjects who meet eligibility during the screening period (Day -60 to 
-2) will be admitted to an inpatient unit (the Vaccine Research Center  
inpatient facility) and have a COVID -[ADDRESS_533774] will be immediately escorted 
out of the unit.  The day after admission to the inpatient unit, eligible participants will be challenged with a dose of human Norovirus GII.4 
CIN-3 Batch No.: 01-16C3. 
The challenge study will be conducted in [ADDRESS_533775] a functional fucosyl transferase-2 ( FUT -2) gene (secretor positive) and 
1 will lack a functional FUT-2 gene (secretor negative). Based on the illness rate of acute gastroenteritis (AGE) in the first cohort, the 
second cohort, and subsequent cohorts, will receive higher or lower doses based on a pre- specified decision tree (as detailed in 
Figure 1).   
 At the time of the cohort admission, 2-[ADDRESS_533776] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           17 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 and virologic evidence of norovirus infection. Subjects will return to 
the investigational site for evaluation on Day 6 (6 -8 days), Day 15 
(14-16 days), Day 30 (28-35 days), Day 45 (40-50 days), and Day 60 
(55-65) post challenge for evaluation of safety, virus shedding and 
clinical evaluations as detailed in Section 7, Table [ADDRESS_533777]  will be performed on Day 
180 (Day 166- 194) to obtain an interim medical history  and capture 
of SAEs that have occurred since the last visit will be solicited.  
Study Phase:   Phase I  
Study Population:   48 generally healthy a dults, 18- 49 years inclusive 
Number of Sites:  [ADDRESS_533778]  or Intervention:  GII.4 norovirus oral challenge  
Study Objectives : 
 Primary   
Determine the  optimal challenge dose of Norovirus GII.4 CIN -3 
Batch No.: 01-16C3 norovirus to achieve illness in ≥50% of subjects  
(illness is defined as norovirus infection determined by [CONTACT_422715]  a) ≥3 loose or liquid stools in a 24-hour period, b)  >300 
gm of loose or liquid stool in a 24-hour period c) and/or any epi[INVESTIGATOR_422673]), during the inpatient period.  
Secondary  
•
 Evaluate the safety of the N orovirus GII.4 CIN-3 Batch No.: 
01-16C3 challenge strain   
• Determine the rate of infection at different challenge doses 
by: 
[CONTACT_295042] 17-[ADDRESS_533779] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           18 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 o Detection of norovirus GII. 4 in the stool using specific 
qRT-PCR  
o Anti- norovirus GII.4 serum IgG by [CONTACT_6428] (≥4 -fold rise 
from baseline to Day 30) 
 
• Measure the severity of acute gastroenteritis  
• Determine the quantity and duration of virus shedding in stool 
by [CONTACT_16641]- PCR  
Exploratory 
• Determine norovirus GII.4 - specific antibody responses  at 
baseline, Day 15 and Day 30  
o Serum IgA and IgG by [CONTACT_6428]  
o Serum Blocking Antibody by E LISA  
• Determine  total and norovirus GII.4 - specific Memory B cell 
response by [CONTACT_422716] 
• Determine the effect of baseline norovirus antibody levels 
(serum IgG, IgA, and blocking antibody) on becoming 
infected with norovirus 
• Determine total and norovirus GII.4 - specific IgA - and IgG-
Antibody Secreting Cells by [CONTACT_422717] : Samples of blood (serum and PBMCs) and stool will be 
collected at various time points as listed on the schedule of events. 
The samples will be processed and archived for future testing .   
DMID Protocol 17-[ADDRESS_533780] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533781] Participation:  6-8 months (screen, inpatient challenge and outpatient follow-up) 
Estimated Time to Last 
Subject/Last Study Day :   Approximately 12- [ADDRESS_533782] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           20 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
  Figure 1: Schematic of Study Design  
 
 
 
“Final” is the dose to be used in the future and not within this protocol . 
 

DMID Protocol 17-[ADDRESS_533783] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           21 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 1 KEY ROLES  
 
Individuals:  
Site Principal Investigator:  
 
 
                                   
[INVESTIGATOR_422674]: Robert W. Frenck, Jr., MD  
Professor of Medicine and Pediatrics  
Director, Vaccine Research Center  
Cincinnati Children’s Hospi[INVESTIGATOR_422675], RN, MSN Nurse Consultant, Clinical Project Manager  
NIAID Virology Branch  
Enteric and Hepatic Diseases Branch, NIH  
BG 5601FL RM 8F56 [ADDRESS_533784]  
Rockville, MD [ZIP_CODE] Phone: [PHONE_8768] 
Email: [EMAIL_8090]  
 
Statistical and Data  
Coordinating Center   
The Emmes Corporation  
[ADDRESS_533785]., Suite 700 Rockville, MD [ZIP_CODE] Phone: [PHONE_2269] Email: [EMAIL_5249]  
 
DMID Protocol 17-[ADDRESS_533786] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           22 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 2 BACKGROUND AND SCIENTIFIC RATIONALE  
2.1 Background 
Norovirus (NoV) is a family of single -stranded, positive -sense RNA (Ribonucleic Acid) viruses 
that are a leading cause of gastroenteritis worldwide as well as the leading cause of foodborne-
associated diarrheal outbreaks in the [LOCATION_002]. The Centers for Disease Control  (CDC) 
estimates that on an annual basis NoV is associated with 267M cases globally  and 21M cases in 
the [LOCATION_002]  with 71,000 U.S. hospi[INVESTIGATOR_602] . NoV is particularly problematic in the 
extremes of age. On a yearly basis, throughout the world, NoV causes over 200K deaths/year, 
especially in children less than 5 years of age and is a common cause of ER visits and hospi[INVESTIGATOR_422676]
1. In the US, NoV is estimated to be the cause 
of death of approximately 800 people over 65 years of age per year. All age groups are 
susceptible to NoV- related disease. Part of the reason is the diversity of NoV. Three different 
genogroups (GI, GII, and GIV) are capable of infecting humans, with ≥[ADDRESS_533787] occurred in 
childcare  centers, schools, restaurants, summer camps, hospi[INVESTIGATOR_600], nursing homes, ships (both 
civilian and military) as well as deployed military troops. The minimal infectious dose may be as 
low as  [ADDRESS_533788], via 
aerosols from vomit, and in contaminated ground waters3. NoV disease occurs throughout the 
year, though major outbreaks tend to occur during winter months. 
NoV are difficult to study  because: 1) they are genetically , and antigenically highly diverse and 
multiple strains co -circulate in the same communities, making diagnosis and disease control 
extremely difficult; 2) the virus cannot be cultivated long term in cell culture; and 3) no small 
animal model exists for studying human NoV. Several animals have been tested as potential 
models, including macaques, chimpanzees, and gnotobiotic pi[INVESTIGATOR_14107]. Although chimpanzees can be 
infected with human NoV, they do not become ill4. Therefore, humans represent the only 
complete disease model  for studying human NoV.   
As not everyone gets infected or ill when exposed, it has been determined that susceptibility to 
NoV is modulated in part by [CONTACT_203935], genetically determined carbohydrates in the gut known as 
the Histo -blood Group Antigens (HBGAs)5. These carbohydrates are found on the surfaces of 
red blood cells and mucosal epi[INVESTIGATOR_24603]. These antigens are also found circulating as free 
oligosaccharides in milk, saliva, and blood. Approximately 80% of humans (termed secretors) 
DMID Protocol 17-[ADDRESS_533789] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533790] a functional fucosyl transferase -2 (Fut-2) gene that leads to expression of HBGAs to which 
many NoVs can adhere. The remainder of the population lack a functional Fut-2 gene and are 
referred to as “non -secretors”. Only secretor- positive individuals can be infected with Norwalk 
Virus (NV), a genogroup 1 virus, supporting the theory that the H type 1 antigens are the cellular receptors for NV. Other HBGAs can also function as receptors, and different norovirus genogroups exhibit unique patterns of HBGA binding
6. Additionally, challenge studies with 
Snow Mountain virus (GII.2) and outbreak studies with other GII viruses have reported 
infections in secretor negative individuals, suggesting the use of receptors other than the secretor -associated HBGAs
7,8.   
A GII.[ADDRESS_533791] 
demonstrated that CIN- 1 is infectious and induces a transient clinical illness of mild to moderate 
severity9. Forty healthy adults (23 secretors (predicted high susceptibility to infection) and 17 
non-secretors (predicted low susceptibility to infection) with low serum antibody levels to GII.4 
(ELISA IgG ≤1:1600) were administered an oral dose of 4.4x104 RT-PCR units (equivalent to 
3.5x105 genome copi[INVESTIGATOR_014]/mL ) of CIN -1. Of the 23 secretors, 16 (70%) were infected with 
norovirus, 13 (57%) became ill (characterized by [CONTACT_422718]/or diarrhea), and 12 (52%) developed norovirus-associated illness. In contrast, only 1 non- secretor (5.9%) became ill  but did 
not have norovirus identified from the stool , and another non -secretor shed virus for a single day  
but was asymptomatic (P <.001 for each variable, compared with secretors). Infection occurred in secretors regardless of ABO blood group
9.  
A second protocol was completed recently at Cincinnati Children’s Hospi[INVESTIGATOR_29349]  
(CCHMC) to determine whether a lower dose of CIN -1 would induce infection (unpublished). A 
total of 38 healthy, adult subjects (34 secretors and 4 non- secretors) with low serum antibody 
levels to GII.4 (ELISA IgG ≤1:1600) were administered 4.4 x103 RT-PCR units of CIN -1 
(unpublished data). Of the 34 secretors, 26/34 (76%) had norovirus detected in the stool by [CONTACT_937]-PCR testing and/or a fold -fold rise in antibodies agains t GII.4 norovirus (unpublished data). In 
contrast, none of the [ADDRESS_533792] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           24 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 2.2 Scientific R ationale  
The initial outbreak of norovirus in Norwalk, Ohio was a GI.112. This isolate has been stored at 
the NIH as well as Baylor College of Medicine (Houston, [LOCATION_007]). The isolate has been used in 
clinical trials and the dose needed for the human infectious dose 50% (HID 50) has been 
determined13. This isolate also has been used in a challenge model to evaluate a genogroup I 
virus- like particle (VLP) vaccine14. However, currently, most NoV infections  are due to 
genogroup II viruses and there is thought to be little to no cross -protection between genogroups. 
2,15. Therefore, the GI.[ADDRESS_533793] dose capable of 
inducing infection in 50% of the susceptible subjects has not been determined. This information 
is critical to the testing of agents designed to prevent or treat NoV. Concerns are that using a 
dose of NoV in excess of what a subject typi[INVESTIGATOR_422677] a promising vaccine or therapeutic. To facilitate these studies, dose range studies for both infection and illness for new GII inoculums must be completed. Once the shape of the dose- response relationship has been characterized, the optimal sample size and most 
efficient challenge doses needed for future trials can be accurately determined, limiting the expense, doses utilized, and health risk of these trials. By [CONTACT_422719]-response relationship, future vaccine and therapeutic studies can make most efficient use of valuable challenge strains  (i.e., a critical dose- sparing efficiency).  Furthermore, with well- characterized 
challenge strains, we can more accurately estimate the efficacy of the vaccine or therapeutic 
treatment with minimal error in the estimate of the predicted infection rate without the vaccine.  
As discussed above, for CIN-1 (GII.4) both a 4.4x10
4 RT-PCR unit and 4.4x103 RT-PCR unit 
dose resulted in approximately 70% of susceptible subjects being infected and nearly 60% 
becoming ill following challenge9 (and unpublished) . However, these doses still exceed that used 
in other challenge studies and may exceed the amount that occurs with natural exposure. Therefore , this higher titer may not be appropriate for vaccine evaluations. Thus, further study to 
evaluate decreases in dose levels is needed. Quantification of the prior CIN -1 challenge strain  
with a titer of 4.4x10
4 RT-PCR units/mL resulted in an updated titer of 3. 5x105 copi[INVESTIGATOR_014]/mL. 
Based on the rate of infection and disease (infections plus symptoms including vomiting and/or 
diarrhea) in the initial cohort; the dose for the second cohort will be selected. Similarly, based on 
the response in the second cohort, the dosing for the 3rd cohort wi ll be determined.   
DMID Protocol 17-[ADDRESS_533794] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           25 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 
 Purpose of Study  
Determine the minimum dose of Norovirus GII.4  CIN-3 Batch No.: 01-16C3 required to produce 
virus- associated  illness in ≥50% subjects .   
 Study Population  
Healthy, non-pregnant adults, 18- 49 years inclusive , negative for COVID -19 by [CONTACT_422720] , will be enrolled into this study. 
Pregnant women will be excluded for safety purposes. 
2.3 Potential Risks and Benefits 
 Potential Risks  
Blood Collection/Intravenous Catheter Placement  
Drawing blood may cause transient discomfort and may cause people to feel faint. Bruising at 
the blood draw site may occur but can be prevented or lessened by [CONTACT_92233]. Infection at the site of blood collection is a rare but possible event. If required for 
intravenous fluid hydration, placement of an intravenous catheter may be associated with mild 
pain, redness and bruising which may take up to 10-14 days to resolve. Rarely, infection or a blood clot may develop. Risks of blood collection and intravenous catheter placement will be minimized by [CONTACT_422721].  
Receipt of 2% sodium bicarbonate solutions  
Based on previous experience with NoV challenges, sodium bicarbonate solution used to buffer 
the stomach before and after administration of the challenge strain will taste salty . 
Receipt of Study Agent (NoV GII.4 Challenge Strain)  
Based on prior GII.4 studies, after receipt of a dose of NoV, it is expected that up to 70% of 
susceptible subjects (secretors) will become infected (i.e. shed NoV in their stool) and 50-60% of 
secretors will develop disease ( vomiting, diarrhea ). In our experience of over [ADDRESS_533795] been administered GII.4 CIN-1; symptoms typi[INVESTIGATOR_422678] a [ADDRESS_533796] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533797] in 
our previous studies has been managed successfully with oral rehydration solution (ORS)  
without need of intravenous fluids.  Although not known to occur, it is possible that subjects could have a hypersensitivity reaction to 
the challenge strain material. Since NoV  challenge virus strains  cannot be produced in a 
laboratory by [CONTACT_244511], the challenge NoV strains are made from human stool filtrates with a 
known viral concentration. The GII.4 challenge to be used in this study was isolated in 2011 
from a stool sample collected as part of our inpatient challenge model of norovirus (Subject 
02CCI 0249). The donor was tested and negative for anti- HAV IgM,  HBsAg, anti -HCV as well 
as HIV  (Human I mmunodeficiency Virus ). He also had stool culture for routine enteric 
pathogens and stool ova and parasite examination, again, all of which w ere negative. However, 
despi[INVESTIGATOR_422679], there is a slight risk of exposure to other infectious agents when subjects are administered the challenge product.  
Peri-anal Dermatitis  
Another possible risk following challenge is peri- anal dermatitis, as a result of diarrhea.  
Spread of the NoV Challenge Strain 
To minimize the likelihood of transmission of virus to study staff from a subject, study staff will 
use good hand hygiene procedures while in the inpatient facility and wear gowns and gloves for activities involving contact [CONTACT_108804]. Face masks will b e worn if the subject is actively 
vomiting.  
Subjects will be advised to wash their hands frequently, especially after toilet use and before 
meals. Subjects will receive counseling and education about the acute gastroenteritis associated 
with NoV and the necessary precautions to minimize the potential for spread of disease to others prior to discharge. At the time of discharge from the inpatient facility, subjects may still be 
shedding NoV in their stools. The exclusion criteria for subjects for th is research study have been 
chosen to minimize the pot ential for a subject to transmit NoV to those at highest risk of severe 
disease (e.g., the elderly, young infants, and immunocompromised individuals)
9,13.  
 
DMID Protocol 17-[ADDRESS_533798] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           27 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Acquisition/Spread of COVID-19 
The pandemic of COVID-19, which began in Wuhan, China in December 2019, continues as of 
the time of the amended protocol (October 2021). To minimize the risk of participants acquiring and/or spreading COVID- 19, all participants will have a negative test for COVID -[ADDRESS_533799]. However, the results of the study could benefit society by [CONTACT_422722] a dose of NoV to be used in future trials testing candidate vaccines and/or therapeutics.   
DMID Protocol 17-[ADDRESS_533800] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533801] a 
functional FUT-2 gene ( secretor positive) and 1 will be chosen because they lack a non -
functional FUT-2 gene (non- secretor). Every subject in a cohort will receive the same dose of 
norovirus. From previous studies we have conducted with this GII.4 norovirus, only 1 “non-secretor” became infected and the symptoms experienced were very mild.  Thus, administration 
of a dose of a GII.[ADDRESS_533802] administering a placebo . 
Based on the illness rate of subjects meeting the primary outcome measure in secretor positive 
subjects of the initial cohort, a series of decision rules will be implemented (see Section 10.2) 
with regards to dosing of the second cohort and third cohort.   
Subjects will remain in the inpatient facility for at least four days  following challenge and 
assessed daily for clinical and virologic evidence of norovirus infection. Discharge criteria are listed in Section  6.1.3. Subjects will return to the investigational site for e valuation on Day 6 (6-8 
days), 15 (14-16 days,), 30 days (28-35 days), 45 (40-45 days), and 60 (55-65 days) post 
challenge.    
Approximately [ADDRESS_533803] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           29 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 3.2 Study Objectives  
 Primary  
Determine the optimal challenge dose of Norovirus GII.4 CIN-3 Batch No.: 01-16C3 norovirus 
to achieve illness in ≥50% of subjects ( illness is defined as norovirus infection determined by 
[CONTACT_422723]  a) ≥3 loose or liquid stools, in a 24-hour period, b)  >300 gm of loose or 
liquid stool in a 24- hour period c) and/or any epi[INVESTIGATOR_254962]), during the inpatient period. 
 Secondary  
Evaluate the safety of the  Norovirus GII.4 CIN -3 Batch No.: 01-16C3 challenge strain   
Determine the rate of infection at different challenge doses by:  
• Detection of norovirus GII. 4 in the stool using specific qRT- PCR  
• Anti- norovirus GII.4 serum IgG by [CONTACT_6428] (≥4- fold rise from baseline through Day 30) 
Measur e the severity of a cute gastroenteritis  
Determine the quantity and duration of virus shedding in stool by [CONTACT_16641]- PCR  
 Exploratory 
Determine norovirus GII.4 - specific antibody responses  at baseline, Day 15 and Day 30 
• Serum IgA and IgG by E LISA  
• Serum Blocking Antibody by E LISA  
Determine total and norovirus GII.[ADDRESS_533804] of baseline norovirus antibody levels (serum IgG, IgA, and blocking 
antibody) on becoming infected with norovirus. 
Determine total and norovirus GII.4 - specific IgA - and IgG-Antibody Secreting Cells  by 
[CONTACT_422724] S amples/ Assays  
Samples of blood (serum and PBMCs) and stool will be collected at various time points as listed 
on the schedule of events. The samples will be processed and archived for future testing.  
DMID Protocol 17-[ADDRESS_533805] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           30 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 3.3 Study Endpoints or Outcomes Measures 
 Primary  
The occurrence of NoV- associated illness ( vomiting, diarrhea, positive PCR ) in secre tor positive 
subjects through Day 4 after challenge.  
 Secondary  
The number of subjects with solicited  adverse events through Day 10. 
The number of unsolicited  serious adverse events reported through Day 180. 
The number of unsolicited  Grade 3 adverse events from challenge to Day 30.   
The number of subjects with infection  through Day 30 as determined by: 
• Detection  of norovirus GII.4 in stool by [CONTACT_16641]- PCR at Days 2, 3, 4, 5, 6, 15, 30 
• ≥4-fold rise from baseline in GII.4 -specific antibody titers in serum IgG by [CONTACT_422725] 30 
Peak genome equivalent copi[INVESTIGATOR_014]/mL of virus in stool as measured by [CONTACT_16641]- PCR after challenge 
through Day 60.  
Duration (number of days) of viral secretion as measured by [CONTACT_16641]-PCR after challenge through 
Day 60. 
Modified Vesikari score through Day 4. 
Duration (hours) of vomiting and/or diarrhea  through Day 5.  
 Exploratory 
Number of subjects with ≥4- fold rise from baseline in GII.4 -specific antibody titers in serum 
(IgA, IgG, Blocking Antibody) by [CONTACT_159304] 15 and Day 30. 
Baseline NoV GII.4 serum  IgG, IgA, and blocking antibody titers  in subjects with and without 
infection .  
Norovirus GII.4- specific Memory  B cells  determined by [CONTACT_422726] 
(Ratio of antigen specific spot forming cells / 106 PBMC) baseline, Day s [ADDRESS_533806] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533807] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           32 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 4 STUDY INTERVENTION/INVESTIGATIONAL 
PRODUCT  
4.[ADDRESS_533808] Description  
As part of the studies where our GII.4 strain was used in human challenges; samples of diarrhea 
were saved from all subjects who developed  diarrhea after receiving the challenge strain. These 
stool samples were aseptically transferred to storage containers and have been maintained at      
<-600C in a temperature monitored freezer for subsequent use. Due to exhausting the supply of 
our original GII.4 challenge pool; samples collected from a subject in our challenge studies has been used to prepare a new chall enge pool. 
The GII.4 challenge to be used in this study was isolated in 2011 from a stool sample collected a
s part of our inpatient challenge model of norovirus (Subject 02CCI0249). The donor is a male 
who was [ADDRESS_533809] of 55 international units (IU) (normal range 30-65 IU). The stool donor received a dose o f the previous challenge strain (CIN-1) on October 24, 2011. The following 
day, the donor began to develop diarrhea which lasted [ADDRESS_533810] to be used in the current study; [ADDRESS_533811] ( Norovirus GII.4 CIN -3 Batch No.: 01- 16C3 ) was prepared by 
[CONTACT_161572] a series of processing steps, including dilution of the original donor specimen, centrifugation, filtration, and filling. Aliquots of t he unfiltered stool sample (10% dilution of the 
2 pooled diarrheal stool samples) was tested  for rotavirus, enteric adenovirus, astrovirus, 
hepatitis A, HIV -1, HIV-2, cytomegalovirus, hepatitis B virus, and hepatitis C virus, as well as in 
vitro  and in vivo  adventitious viral contamination ( in vitro  AA (amino acid) and in vivo  AA). 
Samples of the final product, Norovirus GII.4 Norovirus GII.4  CIN-3 Batch No.: 01-16C3, were 
tested for sterility, identity and potency by [CONTACT_4503]- PCR, direct and indirect methods for 
the detection of mycoplasma, as well as bacterial endotoxin.   
DMID Protocol 17-[ADDRESS_533812] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533813] Norovirus GII.4  CIN -3 Batch No.: 01-16C3 was aliquoted into 
sterile 2mL centrifuge tubes with fill volumes of 1-1.5mL at a concentration of approximately 
3.5x105 copi[INVESTIGATOR_014]/mL . The challenge material  is clear to amber in color and is being stored at                      
<-600C in a temperature monitored freezer.   
This study product is a live, infectious agent capable of causing  symptoms of fever, headache, 
nausea, abdominal cramps/discomfort/pain, abdominal gurgling, abdominal bloating, myalgia, 
malaise/fatigue, anorexia/loss of appetite, and chills . 
 Formulation, Packaging, and Labeling  
Norovirus GII.4 CIN-3 Batch No.: 01-16C3                                                                                                         
The filled, purified study product is formulated in  sterile water for injection, USP in 2mL sterile 
cryovials, in volumes of 1-1.5mL at a concentration  of 3.5x105copi[INVESTIGATOR_014] /mL.  
The study product will be labeled according to manufacturer or regulatory specifications and include the statement “Caution: New Drug – Limited by [CONTACT_12201] ” 
Diluent -
 Sterile Water for Injection, USP  
The sterile water for injection, USP is non -pyrogenic and contains no bacteriostatic, 
antimicrobial agent, or added buffer. This product will be used to dilute the Norovirus GII.4 CIN-3 Batch No.: 01-16C3 and will be supplied as a 2 mL single-dose cryovial. 
A label with the statement “Caution: New drug - Limited by [CONTACT_422727] U se” 
will be placed on the immediate package. 
Buffer - Sodium Bicarbonate, USP  
The Sodium Bicarbonate, USP is a white, odorless, crystalline powder. This product will be used 
to prepare the buffer.  
A label with the statement “Caution: New drug - Limited by [CONTACT_12201]” 
will be placed on the immediate package.  
 
DMID Protocol 17-[ADDRESS_533814] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533815] be manually recorded daily (excluding non- business 
days and holidays, as applicable) and continuously monitored and recorded during the course of 
this trial per the participating VTEU site standard operating procedures (SOPs), and documentation will be maintained. If the temperature fluctuates outside of the required range,  the 
affected study product(s) must be quarantined at the correct storage temperature and labeled as 
‘Do Not Use’ (until further notice). The participating VTEU site’s research pharmacist must alert 
the site principal investigator [INVESTIGATOR_32528], if the temperature fluctuates outside of the required range. In the event the temperature fluctuates outside of the required range, including accidental deep -freezing or disruption of the cold chain, the affected study product(s) must not 
be administered. The site principal investigator [INVESTIGATOR_422680] [EMAIL_5255] for further 
instructions before any additional study product(s) are administered . Based on the information 
collected, DMID and/or the manufacturer will determine whether the affected study product(s) 
can be used. If it cannot be used, the site will receive specific instructions on how to return the affected study product(s) to the DMID CMS or destroy it on site . Additional instructions for 
quarantine and DMID contact [CONTACT_295025]- specific MOP.  
Norovirus GII.4 CIN-3 Batch No.: 01-16C3 
The filled, purified challenge material, Norovirus GII.4 CIN -3 Batch No.: 01-16C3, is  stored at  
≤-60°C in a temperature controlled and continuously t emperature monitored freezer.  
Stability : As norovirus is not cultivatable, nor able to infect other than in a human challenge 
model; it is not possible to perform typi[INVESTIGATOR_422681]. However, the product will be tested 
for copy units by [CONTACT_5203]- time PCR prior to starting the trial and each year while this protocol is 
active. While a consistent real -time PCR titer dose not demonstrate the virus is still alive and 
infectious; based on previous experience of a GI.1 virus being infectious after 30 years of storage; we will assume that the Norovirus GII.4 CIN-3 Batch No.: 01-16C3 is viable and 
infectious if the viral copy number is within 20% of the copy number from the previous year.   
Diluent -
 Sterile Water for Injection, USP  
• The sterile water for injection, USP vials will be  stored at 20°C to 25°C (68°F to 77°F). For 
excursions between 15 -30°C (59°F to 86°F), the product can continue to be used (no 
quarantine) but the site needs to complete the DMID Study Product Support Team Temperature 
DMID Protocol 17-[ADDRESS_533816] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533817].  Based on USP guidelines, excursions between 
15°C and 30°C are allowed and will not be considered deviations. 
 
 Buffer - Sodium Bicarbonate, USP  
• The sodium bicarbonate used to prepare buffer , USP container will be  stored at  20°C to 25°C 
(68°F to 77°F). For excursions between 15- 30°C (59°F to 86°F), the product can continue to 
be used (no quarantine) but the site needs to complete the DMID Study Product Support Team 
Temperature Excursion Reporting Form and submit to PST.   Based on USP guidelines, 
excursions b etween 15°C and 30°C are allowed and will not be considered deviations.  
4.2 Acquisition/Distribution  
The Norovirus GII.4 CIN-3 Batch No.: 01-16C3 will be received by [CONTACT_422728]. Ming 
Tan at Cincinnati Children’s Hospi[INVESTIGATOR_29349] ( Tan Laboratory).   
Diluent - Sterile Water for Injection, USP  - The sterile water for injection, will be  provided by 
[CONTACT_7105].  CCHMC will ship the  sterile w ater for injection, USP, to CMS, Fisher BioServices.  
Buffer - Sodium Bicarbonate, USP – The sodium bicarbonate for buffer will be provided by 
[CONTACT_7105].  CCHMC will ship the  sodium bicarbonate, USP, to CMS, Fisher BioServices. 
4.3 Protocol- Specified Medications/Treatments other than Study 
Products  
Subjects who develop diarrhea will be asked to drink 1.5 mL  of ORS  for each gram of diarrheal 
stool that they produce. Subjects developi[INVESTIGATOR_422682] a volume of ORS equivalent to the amount of the emesis. Subjects unable to drink sufficient ORS to maintain their hydration status may be provided intravenous fluids to prevent and treat dehydration. Therapi[INVESTIGATOR_422683] (excluding ORS) will be recorded as 
concomitant medications. Subjects will be al lowed to continue eating solid foods if they think 
they are well enough to tolerate a meal.  
At the investigator’s discretion and at the subject’s request, subjects may be prescribed 
acetaminophen (or equivalent) for fever, headache, muscle aches, abdominal pain or other 
DMID Protocol 17-[ADDRESS_533818] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533819] has reached a high 
severity of illness and is at risk of requiring intravenous therapy if the emesis is not controlled. 
Ondansetron - (Orange Book #020781, Zofran® Oral Disintegrating Tablet) or its licensed 
equivalent may be administered as prescribed by [CONTACT_093]. See the package insert for further dosing instructions. If the subject is unable to tolerate fluids by [CONTACT_422729], a 0.9% sterile saline solution 1- liter 
bolus will be administered intravenously. Based on additional assessments, replacement intravenous fluids may be continued at investigator discretion.  
4.4 Dosage /Regimen,  Preparation, Dispensing  and Administration of 
Study Intervention/Investigational Product 
Refer to protocol- specific Manual of Procedures ( MOP ) for detailed instructions on the 
preparation, dispensing, and administration of the study product. 
Investigational agents : T he agent used in this subject challenge trial is a safety tested Norovirus 
GII.4 CIN -3 Batch No.: 01-16C3 inoculum (IND number pending).  
Route and Frequency of Administration : S ubjects will receive a single oral dose of Norovirus 
GII.4 CIN -3 Batch No.: 01-16C3 on Day 1 of their inpatient stay at the clinical site .  
Norovirus dosage : th e initial cohort will be receiving 3.5x103 copi[INVESTIGATOR_422684] . This dose 
was chosen as the starting dose because from a previous GII.4 NoV challenge study at CCHMC, approximately the same dose resulted in a 70% rate of infection and 50% rate of disease.   
Dosage for subsequent cohorts will depend on the results of the first cohort, per Figure 1. 
Preparation of dose :
  On the day of Norovirus challenge, the study product will be removed 
from the freezer and thawed on wet ice for  approximately  30 minutes. The undiluted (stock),  
which contains approximately 3.5 x105 copi[INVESTIGATOR_014]/mL of the challenge virus, will be diluted further 
with sterile water for injection, USP to a volume sufficient in order to have the desired 
challenge dose contained in [ADDRESS_533820] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           37 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Prior to administration to the subjects, an  aliquot of the final dilution of the challenge strain will 
be placed in a freezer tube, labeled according to contents, and kept on wet ice for no longer than 
8 hours until stored frozen at ≤600C (see MOP specifications) . This aliquot will be used to 
confirm the dose of norovirus administered to the subjects. Any remaining portion of the thawed aliquot that is not used the day the sample is thawed will be discarded.  
The final subject use material  (cup) is labeled with the patient’s initials and study ID, the 
time/date of final preparation, an expi[INVESTIGATOR_299995], and the statement “ CAUTION- 
FEDERAL LAW PROHIBITS THE USE OF THIS PRODUCT EXCEPT FOR 
INVESTIGATIONAL USE ”. The final patient use material is stored short term at either 2 -8
oC or 
held on wet ice for no more than 8 hours. 
Administration : O nce prepared, the challenge dose must be given within [ADDRESS_533821] clear liquids within 4 hours of challenge but will be NPO 
(nothing by [CONTACT_1966]) for at least 90 minutes prior to  ingestion of 60 mL of a 2% sodium 
bicarbonate solution by [CONTACT_1966]. Approximately 2 minutes later, subjects will be administered the final patient use material. Approximately five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next [ADDRESS_533822] and treat 
any immediate adverse reactions.  
4.5 Pre-determined Modification of Study Intervention/Investigational  
Product for an Individual Subject  
If a subject vomits the sodium bicarbonate solution or challenge dose, the  dose will not be 
repeated.  
4.6 Accountability Procedures for the Study Intervention/Investigational Product(s) 
Once received, the challenge material will be stored in and dispensed by [CONTACT_156979].   
The Food and Drug Administration (FDA) requires accounting for the disposition of all 
investigational products. The Investigator is responsible for ensuring that a current record of product distribution and disposition is maintained , and product is dispensed only at an official 
study site by [CONTACT_202413]. Records 
DMID Protocol 17-[ADDRESS_533823] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533824] to in spection by a regulatory 
agency (e.g., FDA) at any time. An assigned Study Monitor will review the pharmacy records. 
Vials will be stored at ≤ 600C until thawed and used. Used and unused vials of challenge strain 
and an aliquot of the final dilution of the challenge strain  will be stored at ≤ -60°C in a 
temperature controlled and continuously temperature monitored freezer in the Investigational 
Pharmacy until clinical trial accountability  is completed  and DMID provides instruct ions for 
disposition of the unused vials. At study termination, all unused investigational product will be handled in accordance with the MOP following complete drug accountability and monitoring.  
DMID Protocol 17-[ADDRESS_533825] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533826] 
Inclusion/Exclusion Criteria in DMID -sponsored studies. Questions about eligibility will be 
directed toward the DMID Medical Officer.  
 Subject Inclusion Criteria  
1. Subject able to provide informed consent. 
2. Male or non-pregnant females between the ages of [ADDRESS_533827]- menopausal (absence of 
menses for > 1 year) or surgically sterilized (tubal ligation, bilateral oophorectomy or 
hysterectomy).  
o Acceptable contraception methods for women include but are not limited to: sexual abstinence from intercourse with men, monogamous relationship with vasectomized partner who has been vasectomized for [ADDRESS_533828] enrolling in the study, barrier methods such as condoms or diaphragms with spermicide or foam, effective devices (IUDs, NuvaRing ®) or licensed hormonal 
products such as implants, injectables or oral contraceptives.  
4. For women of childbearing potential, must have a negative serum or urine pregnancy test at screening.  
5. Are in good general health*.  
* As determined by [CONTACT_422730], defined as those that have been present for 
at least [ADDRESS_533829] 60 days (no hospi[INVESTIGATOR_602], Emergency Room (ER), or urgent care for condition and no adverse symptoms that need medical 
intervention such as medication change/supplemental oxygen). This includes no change in 
chronic prescription medication, dose, or frequency as a result of deterioration of the chronic 
medical diagnosis or condition in the [ADDRESS_533830] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           40 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 is due to change of health care provider, insurance company, etc., or that is done for financial 
reasons, as long as in the same class of medication, will not be considered a deviation of this 
inclusion criterion. Any change in prescription medication due to improvement of a disease 
outcome, as determined by [CONTACT_16541] [INVESTIGATOR_29353] -investigator, will 
not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as 
needed (prn) medications if, in the  opi[INVESTIGATOR_29352] -
investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition. Similarly, 
medication changes subsequent to enrollment and study vaccination are acceptable provided there was no deterioration in the subject’s chronic medical condition that necessitated a 
medication change, and there is no additional risk to the subject  or interference with the 
evaluation of responses to study vaccination.  
6. Demonstrate knowledge and comprehension of the study by [CONTACT_88687] ≥70% on a quiz (test 
of understanding) of the study protocol and policies. 
7. Willing and able to participate in all study visits, including an inpatient stay of at least [ADDRESS_533831] Exclusion Criteria  
Subjects who meet any of the following exclusion criteria will be excluded from study participation: 
1. Have household contact [CONTACT_422731] [ADDRESS_533832]  (> 2 hours/day) with immunocompromised 
individuals in the 8 weeks after challenge*. 
* Including persons with HIV infection or active cancer, children <2 years of age, pregnant 
women or persons who are immunosuppressed (e.g. history of stem cell or organ 
transplantation) and/or provide any child day care services (in-home or non-residential 
facility) . 
3. Are healthcare workers with direct patient contact [CONTACT_422732] (in -home or 
non-residential facility ) in the [ADDRESS_533833] at the time of admission to  the challenge 
unit. 
5. Are food service workers expected to prepare/handle food in the 8 weeks after challenge. 
6. Plan to be living in a confined communal environment (e.g. ship, camp, or dormitory) 
within [ADDRESS_533834] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533835] a history of acute gastroenteritis in the 4 weeks prior to challenge or any history of 
chronic or recurrent diarrhea or vomiting .  
10. History of significant GI  condition.*                                                                                      
*Including: malabsorption, major GI  surgery, current *eating disorder, irritable bowel 
syndrome, or any GI disorder (deemed clinically significant by [CONTACT_70852]) making  it unsafe 
to participate . 
11. H ave significant acute illness or an oral temperature >100.4°F within seven days prior to 
challenge. 
12. H ave a heart  rate <45 beats per minute (bpm) or >100 bpm*.  
* If heart rate is < 45 beats per minute and the investigator determines that this is not clinically  
significant (e.g., athletes) and heart rate increases > 45 beats per minute on moderate exercise 
(two flights of stairs), subject will not be excluded.  If a subject has significant abnormalities in 
their heart rate, they will be informed of the values and advised to seek care from their physician.  
13. Systolic blood pressure less than 90 mm Hg or greater than 150 mm Hg on two separate 
measurements (screening and baseline pr ior to challenge) .                                                                          
* If a subject has significant abnormalities in their blood pressure, they will be informed of the 
values and advised to seek care from their physician.  
14. Diastolic blood pressure less than 50 mm Hg or greater than 90 mmHg on two separate 
measurements (screening and baseline, prior to challenge) .  
15. H ave long- term use ( >2 weeks) of high-dose oral (>20 mg per day prednisone or 
equivalent) or parenteral glucocorticoids, or high- dose inhaled steroids for greater than [ADDRESS_533836] HIV, Hepatitis B , or Hepatitis C *.  
* Subjects will be tested for HIV, Hepatitis B surface antigen, and antibody to Hepatitis C at 
screening only. Any subjects having HIV, Hepatitis B, Hepatitis C infection will not be enrolled into the study. 
18. Have a seizure disorder . 
19. Have an active malignancy or history of malignancy* or current use of immunosuppressive or cytotoxic therapy.  
*Excluding nonmelanotic  skin cancer in remission without treatment for more than [ADDRESS_533837] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533838] results per laboratory reported normal values 
and Appendix B *. 
* For white blood cells (WBCs), hemoglobin (Hgb), platelets, absolute neutrophil count (ANC), 
total bilirubin, potassium, sodium, and urine protein.  
21. Serum creatinine greater than a Grade 1 adverse event on enrollment.  
22. Alanine aminotransferase (ALT), greater than Grade [ADDRESS_533839] a chronic condition that the study physician feels would pose a threat to 
participating subjects *. 
* Including, but not limited to solid organ or stem cell transplantation, diabetes, clinically 
significant history of immunosuppressive illness, gall bladder disease, heart disease, lung 
disease, pancreatic disease, renal disease or neurological disease. 
24. Have ongoing drug abuse/dependence (including alcohol), or a history of these issues 
within [ADDRESS_533840] at any time during the study period* 
* Including study interventions such as drugs, biologics or devices. 
31. Plan to donate blood during the course of the study. 
32. Have received a live vaccine within [ADDRESS_533841] received , or plan to receive, an inactivated vaccine within 14 days of  challenge to 
14 days after challenge.  
34. Received parenteral immunoglobulin or blood products within 3 months of challenge, or 
plan to receive parenteral immunoglobulin/blood products within [ADDRESS_533842] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533843] be recorded in the 
case report forms (CRFs).  
The reasons, might include, but are not limited to the following: 
• Prior to dosing, the s ubject no longer meets eligibility criteria  
• Prior to dosing, the s ubject meets individual halting criteria  
• Subject becomes noncompliant 
• Medical disease or condition, or new clinical finding(s) for which continued 
participation, in the opi[INVESTIGATOR_149048], interfere with the subject's successful completion of this study, or interfere with 
the evaluation of responses 
• Positive for COVID -19 by [CONTACT_422733] 
• Subject lost to follow -up 
• Subject becomes pregnant 
• Determined by a physician’s discretion to require additional therapy not indicated in the 
protocol to ensure subject’s health and well- being (or treatment failure, if applicable)  
DMID Protocol 17-[ADDRESS_533844] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           44 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Whenever possible, subjects should continue to be followed for safety. The investigator should 
be explicit regarding study follow-up (e.g. safety follow-up) that might be carried out despi[INVESTIGATOR_422685]. If the subject consents, every attempt will be made to follow all AEs through r esolution. The procedures that collect safety data for the 
purposes of research must be inclusive in the original informed consent or the investigator may seek subsequent informed consent using an IRB/IEC-approved consent form with the revised 
procedures. 
The investigator will inform the subject that already collected data will be retained and analyzed 
even if the subject withdraws from this study . 
 Subject Replacement  
Subjects who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the informed consent form (ICF) and administration of the study product will not be replaced.  
Subjects who withdraw, or are withdrawn from this study, or are l ost to follow -up after signing 
the ICF but before administration of the study product may be replaced. At the time of admission 
to the inpatient unit, 2-[ADDRESS_533845] in the next cohort. Alternate subjects will be re- screened if their screening information falls outside the protocol designated 
window for a subsequent cohort.   
 Study Termination  
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the 
investigator for any reason, the investigator will promptly inform the study subjects and assure 
appropriate therapy or follow -up for the subjects, as necessary. The in vestigator will provide a 
detailed written explanation of the termination to the IRB/IEC. If any subject’s private information will continue to be collected for this study, the IRB/IEC must approve a consent form with the study procedures, any risks and di scomforts, and applicable elements, and the 
investigator or designee will re -consent the subjects as approved by [CONTACT_1201]/IEC. 
DMID Protocol 17-[ADDRESS_533846] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           45 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 6 STUDY PROCEDURES  
6.1 Screening  Visit 00 A (Day -60 to - 2) 
After signing the informed  consent form , subjects will be carefully screened with a detailed 
medical history and physical examination to ensure they are in good physical and mental health. 
Screening may be completed at one or more visits depending on the subject and the timing of specimen collection. 
Screening evaluations will include the following and may occur over 1 or more visits as 
outlined below : 
An initial screening visit may be scheduled to obtain informed consent, provide educational materials for the test of understanding, review inclusion/exclusion criteria, obtain demographics, measure body weight and vital signs (including oral temperature, blood pressure, and pulse), and 
collect medical history (including concomitant medications  and allergies ).   
Specimens will be collected  for hematology testing (hemoglobin, white blood cells with 
neutrophil count and platelet count), c hemistry panel (sodium, potassium, creatinine, ALT, total 
bilirubin), urine or serum pregnancy testing (for females of childbearing potential ), serology 
including Hepatitis B surface antigen, antibody to Hepatitis C, HIV antibody, and urine 
collection for protein and opi[INVESTIGATOR_858].  Saliva will be collected and tested for secretor status.  R epeat 
testing may be completed at a subsequent vis it. 
Subjects will  be scheduled to have an abbreviated physical (genital-urinary and rectal exam not 
required).  
A test of understanding will be administered prior to challenge. Subjects must pass with a score 
of at least 70%. Anyone not passing the test initially may retake the test with a passing score. 
Screening must take place between 60 and 2 days before enrollment (day of challenge) . Subjects 
whose date of screening falls outside of the screening period must be re -screened before they 
may be enrolled.  Subjects will be given a stool kit to bring a baseline sample to the inpatient challenge.  
If a physiologic parameter, e.g., vital signs, is outside of the protocol-specified range, then the 
measurement may be repeated once if, in the judgment of the investigator, the abnormality is the result of an acute, short -term, rapi[INVESTIGATOR_422686] n (e.g., stress, anxiety, or “white coat 
DMID Protocol 17-[ADDRESS_533847] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           46 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 syndrome”). A physiologic parameter may also be repeated if there is a technical problem with 
the measurement caused by [CONTACT_257937], or an inappropriate measuring device (i.e., 
inappropriate-sized blood pressure cuff). 
If hemoglobin, WBC, platelet or neutrophil count, blood chemistry, or urine protein is out of 
range, then the measurement may be repeated once if there is a medical reason to explain the 
values being out of range. If the repeat value remains out of range but determined by [CONTACT_422734], the  subject may continue. For baseline laboratory 
results that are abnormal according to the local laboratory reference range and fall within Grade [ADDRESS_533848] may be re -screened if there is a transient disease status (e.g., subject complained of a 
“cold or fever” and met a temporary delaying enrollment criterion of acute illness or fever). A 
subject may also be re- screened if the subject was screened eligible for a previous dose group but 
was not enrolled (e.g., subject was an alternate, was unable to produce a baseline stool sample, has scheduling conflict with inpatient admission days, etc.). 
If screening labs are collected outside of the designated window of -[ADDRESS_533849] may be screened  more than twice due to a screening failure result as defined 
above.  Repeating  of a lab value if the original result is out of window is not considered re -
screening for screen failure. Once the screening evaluation is complete, eligibility for continuation to the inpatient challenge portion will be determined . Those who remain eligible 
and are willing to participate will be scheduled for admission to receive the challenge dose. 
Inpatient Stay (Admission Day to post challenge Day 5) 
 
 Screening Visit 00B (Day -1) 
Staff will confirm that subjects have completed informed consent and will be asked to read and 
sign any updated consent document(s).    
DMID Protocol 17-[ADDRESS_533850] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533851] 70%.   
Demographics will be confirmed. Body weight and vital signs (including oral temperature, blood 
pressure, and pulse) will be obtained, and a review of medical history (including concomitant 
medications and allergies) will be completed.  A symptom directed physical exam will be 
performed, females of child -bearing potential will have a confirmed negative urine pregnancy 
test, a COVID-[ADDRESS_533852] will be performed and confirmed as negative, and review of inclusion/exclusion criteria will be performed to ens ure subject eligibility.  
Blood and stool samples will be collected per schedule of events. 
 
 Inpatient Challenge Admission    
Subjects  either may be admitted  the day before challenge  or on the  day of challenge. 
The study will be conducted in the Cincinnati Children’s Hospi[INVESTIGATOR_29349] (CCHMC) 
inpatient unit. The unit has controlled access and is comprised of up to [ADDRESS_533853] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           48 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Review inclusion/exclusion criteria  
Symptom directed physical examination   
Vital signs including oral temperature, blood pressure, and pulse.  
Baseline weight  
Serum or urine pregnancy test for women of childbearing potential (May be done up to 24 hours 
prior to challenge).  
Obtain baseline specimens  per Schedule of Eve nts Appendix A . 
 Blood  will be collected for : 
o norovirus GII.4- specific IgG, IgA and Blocking Antibody, ELISA  
o norovirus GII.4- specific Memory B cells  by [CONTACT_422716]  
o norovirus GII.4- specific ASC  ELISpot  and ALS  by [CONTACT_6428]  
o Future Use  
Stoo l will be collected for:  
o Virus Detection  
o Future Use   
Challenge  Procedure (Day 1)   
Subjects will  not be allowed to eat or drink anything for at least [ADDRESS_533854], subjects will be administered 60 mL of a 2% sodium bicarbonate solution by [CONTACT_1966]. 
Approximately two minutes  later, administer the GII.4 norovirus Challenge Dose  by [CONTACT_1966]. 
(Challenge dose will be prepared as outlined in the Manual of Procedures ) 
Approximately five minutes  following administration of the challenge dose , subjects will be 
administered  a 60 mL  volume of a 2% sodium bicarbonate solution. Subjects will be observed 
closely during the [ADDRESS_533855] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533856] -Challenge : Visit 02-05 (Days 2-5)  
For the remainder of the inpatient period, the following procedures will be performed :  
Vital signs (pulse, blood pressure and oral temperature) will be measured at least daily, more 
often as clinically indicated.  
Weight will be obtained if there are concerns for dehydration.  
Symptom directed examinations will be performed by [CONTACT_422735], more 
often as clinically indicated . 
Assessm ent of  solicited AEs (symptoms of fever, headache, nausea, abdominal 
cramps/discomfort/pain, abdominal gurgling abdominal bloating, myalgia, malaise/fatigue, anorexia/loss of appetite, chills) will be completed at least once daily until discharge.  
Record number of epi[INVESTIGATOR_422687] . 
All stools will be graded for consistency (see Appendix D :  Diarrhea/Vomiting  Grading Scale for 
details), and all loose or watery stools (i.e., those that conform to the shape of the container) will be weighed.   
The first stool of each study day will be collected (study day is defined as 00:00 – 23:59) for 
viral detection .   
Subjects with diarrhea  will have up to 1 stool sample/[ADDRESS_533857] with vomiting and/or diarrhea.  
Evaluation for dehydration. A physician, APN or PA will e valuate subjects who are symptomatic 
and have any of the following:  
• Tachycardia (resting heart rate >100 beats/min)  
• Hypotension (systolic pressure <90 mm Hg or diastolic pressure <50 mm Hg 
accompanied by [CONTACT_422736]) 
• Greater than [ADDRESS_533858] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533859] study samples as described in Schedule of Events Appendix A  and listed below: 
Blood will be collect ed for:  
o Future Use  Day 2 and Day 4 
o Safety Labs (hematology and chemistry) Day 5  if indicated per investigator 
discretion, prior to discharge  
Stool  will be collected for:  
o Virus detection Day 2, Day 3, Day 4, Day 5  
o Future Use  Day 2, Day 4  
 
Treatment of vomiting and/or diarrhea  
See section 4.3 for allowed treatment of vomiting and diarrhea. 
Subjects will remain in the inpatient facility for a minimum of four days following challenge.  
Subjects will be discharged from the inpatient facility when the following criteria are met : 
• At least 96 hours after administration of the norovirus  challenge 
• Afebrile for at least the 12 hours prior to discharge  
• Able to maintain hydration 
• Clinically stable  
• If having any symptoms , they do not interfere with  activities of daily living  
• Received education prior to discharge about the potential for transmission of norovirus to 
others up to [ADDRESS_533860] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           51 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 • Received instructions to contact [CONTACT_422737], all subjects will have the following performed:  
Obtain blood for safety labs, if indicated per investigator discretion , prior to discharge  
Subjects who receive IV hydration during the inpatient admission will be required to have 
clinically acceptable electrolyte values for sodium and potassium prior to discharge.  
Provide subject with a digital thermometer and instructions in its use and asked to take and record their oral temperature once daily at the same time each day for [ADDRESS_533861] with an illness/reactogenicity  (solicited adverse events)  memory aid and instruct 
them to record information for [ADDRESS_533862] to notify the study staff promptly  if they develop any signs or symptoms of 
illness , become pregnant, or require hospi[INVESTIGATOR_48285] 30-day period after challenge 
Instructions on when to return to the outpatient clinic for evaluation  
Provided a stool collection system (“s tool kit ”) and asked to bring a stool sample to the 
outpatient clinic visit  
6.[ADDRESS_533863] Challenge  Visits  
 Visit 06, Day 6 (+2, Day  6-8) 
At th e Day 6  visit, the following procedures will be performed: 
Review interim medical history and record concomitant medications  
Perform a symptom -directed physical exam if indicated  
DMID Protocol 17-[ADDRESS_533864] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533865] vital signs including oral temperature, blood pressure, and pulse 
Blood  will be collected for :  
o norovirus GII.4- specific ASC ELISpot  and ALS ELISA  
o Future Use  
 Stool  will be collected for:  
o Virus detection  
o Future Use   
If the subject was unable to provide a bulk stool sample from home, an attempt will be made to 
have the subject collect a bulk stool during the clinic visit.  
Review the subject’s illness/reactogenicity  (solicited adverse events)  memory aid.  
Remind subject to continue recording illness/reactogenicity  (solicited adverse events)  
information until Day [ADDRESS_533866] with 
develops symptoms of Norovirus infection within a week after being discharged from the inpatient unit.  
 Review of AEs and SAEs  
A stool kit  will be given to the subjects and they will be asked to bring a stool sample with them 
for the next study visit.  
 Visit 07, Day 15 (+/-1, Day 14-16) 
The following procedures will be performed at this visit: 
Review interim medical history and record concomitant medications  
Perform a symptom -directed physical exam (obtain vital signs, if indicated) 
Blood will be collected for:  
DMID Protocol 17-[ADDRESS_533867] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           53 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 o Serum norovirus IgG (including blocking antibody), and serum IgA ELISA  
o norovirus GII.4- specific  ASC ELISpot and ALS ELISA  
o Future Use  
Stool  will be collected for:  
o Virus detection   
o Future Use   
If the subject was unable to provide a bulk stool sample from home, an attempt will be made to 
have the subject collect a bulk stool during the clinic visit.  
Review subject’s illness/ reactogenicity (solicited adverse events) memory aid and c ollect.   
Remind subject to report any unsolicited adverse events through Day [ADDRESS_533868] with has developed  
symptoms of Norovirus infection within a week after being discharged from the inpatient unit.  
A stool kit  will be given to the subjects and they will be asked to bring a stool sample with them 
for the next study visit.  
 Visit 08, Day 30 (-2/+5, Day 28-35) 
The following procedures will be performed at this visit:  
Review interim medical history  
Review and r ecord concomitant medications  
Collect unsolicited adverse events through study Day [ADDRESS_533869] administration Perform a symptom -directed physical exam ( obtain vital signs, if indicated) 
Blood  will be collected for:  
o Serum norovirus IgG IgA ELISA and blocking antibody  
DMID Protocol 17-[ADDRESS_533870] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           54 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 o norovirus GII.4- specific  Memory B- cells  
o Future Use   
Stool  will be collected for: 
o Virus detection   
o Future Use   
If the subject was unable to provide a bulk stool sample from home, an attempt will be made to 
have the subject collect a bulk stool during the clinic visit.  
Review of AEs, Pregnancy, and SAEs  
A stool kit  will be given to the subjects and they will be asked to bring a stool sample with them 
for the next study visit 
 Visit 09, Day 45 (-5/+5, Day 40-50) 
The following procedures will be performed at this visit: 
Perform a symptom -directed physical exam (obtain vital signs, if indicated) 
Review interim medical history  
Stool will be collected for: 
o Virus detection   
Review of pregnancy, S AEs that have occurred since the last visit  
A stool kit  will be given to the subjects and they will be asked to bring a stool sample with them 
for the next study visit 
 Visit 10 Day 60 (-5/+5, Day 55-65) 
Review interim medical history .  
Review of  pregnancy, SAEs that have occurred since the last visit  
Perform a symptom -directed physical exam (obtain vital signs, if indicated) 
Blood  will be collected for: 
o norovirus GII.4- specific Memory B- cells 
DMID Protocol 17-[ADDRESS_533871] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           55 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Stool  will be collected for:  
o Virus detection  
 If the subject was unable to provide a bulk stool sample from home, an attempt 
will be made to have the subject collect a bulk stool during the clinic visit. 
If shedding is detected by [CONTACT_16641]-PCR in the Day [ADDRESS_533872] : Visit 11,  Day 180 ( +/-14, Day 166-194)  
Approximately [ADDRESS_533873] the inpatient facility early (before 4 days after receipt of 
the challenge) due to an emergency, the following activities will be performed:  
• Subjects will be instructed in hand hygiene techniques to minimize the potential spread of 
norovirus to their family members and other close contacts.  
• Subjects will be asked to undergo an evaluation by [CONTACT_093].  
• Scheduled study labs will be collected. 
• Review of AE s and SAEs. 
Subjects will still be asked to complete the illness/reactogenicity  (solicited adverse events)  and 
unsolicited adverse event(s) memory aids , complete procedures indicated for that study day, 
including safety labs if indicated per investigator discretion, and complete all remaining study 
visits and final study contact . 
DMID Protocol 17-[ADDRESS_533874] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533875] needs to be transferred to a hospi[INVESTIGATOR_422688]/her inpatient 
facility stay, the study staff will ask permission of the subject to obtain additional medical records to follow the subject until the symptoms of this seriou s adverse event resolve or the 
subject’s condition becomes stable.  The hospi[INVESTIGATOR_422689]’s participation in this research study so that the subject can be managed in appropriate isolation precautions. 
6.6 Unscheduled Study Visits  
Subjects will be asked to notify the study staff promptly  if they develop any illness suggestive of 
recurrence of the norovirus (vomiting or diarrhea) or possible dehydration. If the study staff determines the symptoms are potentially significant, the subject will be asked to come to the 
clinic for an evaluation.  Subjects will be asked to complete an unscheduled visit for any event 
that warrants follow -up. All events will be followed to resolution or until determined to be 
stable.  
6.[ADDRESS_533876], the site principal investigator, or the site personnel. As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483]. 
These practices are consistent with ICH E6:  
4.[ADDRESS_533877] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533878] ’s chart. Protocol deviations must be sent to the local 
IRB/IEC per their guidelines. The site principal investigator [INVESTIGATOR_422690]. 
DMID Protocol 17-[ADDRESS_533879] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533880] interview  and will include a review of concomitant 
medications, supplements, and over the counter (OTC) medications . Subjects will be queried 
regarding a history of significant medical disorders of the head, eyes, ears, nose, throat 
(HEENT), mouth, cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic, nervous system, blood, lymph glands, endocrine system, musculoskeletal system, skin, and genital/ reproductive tract. A history of any allergies, cancer, gastrointestinal disorders, immunodeficiency, psychiatric illness, substance abuse, and autoimmune disease will be 
solicited.  
Physical Examination  
An abbreviated physical examination will be conducted at the screening visit. An abbreviated 
physical examination is distinguished from a complete physical exam in that all assessments are not required (e.g. genito- urinary and rectal exams). A rectal exami nation may be performed at 
screening if, in the opi[INVESTIGATOR_871], this assessment is warranted based on the subject’s medical history. A symptom directed physical examination may be performed at all 
other study visits if indicated based on, reactogenicity (solicited adverse events)  or interim 
medical history review. 
Inpatient Evaluations  
During the Inpatient Stay, the following clinical evaluations will occur:  
Subjects will be asked to collect every stool passed during the inpatient portion of the study.   
Body weight will be measured on admission to the inpatient unit and repeated during the 
inpatient stay as clinically indicated to evaluate for dehydration.  
Vital signs including oral temperature, blood pressure and pulse will be obtained at least daily , or 
more frequently as clinically indicated   
DMID Protocol 17-[ADDRESS_533881] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           59 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Daily evaluations by [CONTACT_2413], or more frequently as clinically indicated, to check for 
complaints of : fever, headache, nausea, abdominal cramps/discomfort/pain, abdominal gurgling, 
abdominal bloating, myalgia, malaise/fatigue, anorexia/loss of appetite, chills .  
Clinical Laboratory Evaluations  
Clinical laboratory evaluations of the subjects will include collection of blood, urine, saliva, and 
stool. Testing to be performed as outlined in Appendix A . Blood volumes are listed in Table 1. 
Saliva and stool volumes are listed in  Table 2. 
Safety laboratory evaluations will be performed by [CONTACT_422738]. Urine 
screening for opi[INVESTIGATOR_422691]. Urine pregnancy testing and urine dipstick for protein will be performed in the clinic by a qualified study team member using a commercially available 
test. 
Subjects will be tested for HIV, Hepatitis B surface antigen, and antibody to Hepatitis C at  
screening only. For females of childbearing potential, a urine or serum pregnancy test will be performed at screening. Urine or serum pregnancy testing will be performed within [ADDRESS_533882] be negative for subjects to be eligible for participation.   
Saliva will be collected  at screening for determination of secretor status . 
Clinical safety lab testing will include hematology, chemistry and urinalysis with the following 
parameters.  
Hematology: white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin (Hgb), and platelet count 
Chemistry: sodium, potassium, creatinine, ALT, and total bilirubin  
Urinalysis by [CONTACT_124764]. At screening, a result greater than trace protein will make the 
subject ineligible for study participation. Any other parameters on the dipstick having a positive result are not exclusionary and the decision to enroll th e subject is at the discretion of the 
investigator.    
DMID Protocol 17-[ADDRESS_533883] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           60 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Table 1: Venipuncture/Blood Volumes (mL)   
Study Day  Tube 
Type Screening  
(-60 to-2) Admission  
(Day -1)  1 
(day of 
challenge)  2 3 4 5 6 
(+2) 15  
(± 1) 30 
(-2, +5)  45 
(±5) 60 
(±5) TOTAL  
Chemistry and 
Hematology 
Safety Labs  5mL 
EDTA, 
5mL SST  10  10# 10# 10# 10# 10#      [ADDRESS_533884]* (if 
determined by 
[CONTACT_11084])  [ADDRESS_533885] 10            10 
Serum Norovirus 
Antibody (IgG 
and IgA ELISA 
and blocking 
antibody)  [ADDRESS_533886]  10 (10)      10 10   30 
RNAseq assay 
Future Use  2.5 mL 
PAXgene   2.5 (2.5) 2.5  2.5  2.5 2.5 2.5   15 
Protein (cytokine) 
Luminex assays 
(plasma from 
PBMC processing, 
no extra blood)** 
Future Use    x (x) x  x  x x    0 
DC/NK (PBMC)  
Future Use  8.0 mL 
CPT   8 (8) 8  8  8 8    40 
norovirus GII.4 -
specific Memory 
B 
cells/ELISpot 
assay (PBMC)  8.0 mL 
CPT   16 (16)       16  16 48 
norovirus GII.4 —
specific T  
cell/Intracellular 
cytokine 
assay (PBMC) 
Future Use  8.0 mL 
CPT   8 (8)     8 8 8   32 
Norovirus GII.4 —
specific ASC 
ELISpot, ALS 
ELISA  8.0 mL 
CPT   32 (32)     32 32    96 
Total Blood 
Volume  20.0 76.5  10.5  10.5  50.5 60.5 36.5  16 281 
*  volume may vary depending on the gender of the subject (i.e. serum pregnancy testing)  
DMID Protocol 17-[ADDRESS_533887] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           61 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 **  plasma from PBMC processing, no extra blood  
( )  these samples may be collected either on admission or Day 1, prior to challenge. These samples are collected once  within 24 
hours of challenge.   
#    these samples may be collected  at the discretion of the investigator  
  
At the discretion of the investigator or delegate,  urine dipstick may be performed to capture urine 
specific gravity  results in real time.  
 
Table 2. Saliva and Stool Collection  
Study Day  Screening  
(-60 to-2) Admission 
(D
ay -1)  1 (day of 
challenge)  2 3 4 5 6 
(+2) 15  
(± 1) 30 
(-2, +5)  45 
(±5) 60 
(±5) TOTAL 
Saliva sample  X 
5 mL            5 mL 
Stool samples   X (X) X X X X X X X X X**  
** Subjects who continue to shed Norovirus at the Day 60 visit will be followed for clearance  
Research Procedures  
Subjects will be provided with an illness/reactogenicity  (solicited adverse events) memory aid 
and asked to record information regarding diarrhea and vomiting, and any solicited events 
(anticipated systemic reactions) for [ADDRESS_533888] regarding complaints of fever, headache, nausea, abdominal cramps/discomfort/pain, abdominal gurgling, abdominal bloating, myalgia, 
malaise/fatigue, anorexia/loss of appetite, and chills . 
Vomiting (number of times per day and weights) epi[INVESTIGATOR_422692].  
Diarrhea l (as defined per protocol) stools will be weighed, recorded and graded for stool 
consistency . Stool will be collected for virus detection.  
Assessment of Concomitant Medications/Treatments other than Study Product  
DMID Protocol 17-[ADDRESS_533889] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533890], will be recorded. All prescription and over- the-counter 
medications as well as vitamins and supplements will be recorded.  
Assessment of eligibility also will include a review of permitted and prohibited medications (per the exclusion criteria).  
Use of new medications should prompt evaluation for the presence of an adverse event. 
Medications which may interfere with the evaluation of the investigational product should not be 
used unless absolutely necessary. Medications or treatments which are prohibited through study Day 30 include:   
• Vaccines (inactivated vaccines, if clinically necessary, should be administered 14 days 
before or 14 days after challenge) 
• Oral, parenteral or high -dose inhaled steroids 
• Immunosuppressive or cytotoxic therapy 
o Blood products or immunoglobulins 
o Experimental products (through study Day 180) 
Any medications considered for treatment of fever, adverse event, or reactogenicity (solicited 
adverse events) will be given only at the discretion of the study investigator.  
Assessment of Subject Compliance with Study Intervention/Investigational Product/Investigational Device  
Subjects are expected to drink all of the product mixture, as well as 60 mL of 2% sodium bicarbonate, approximately [ADDRESS_533891] will remain in  the study until symptoms resolve and he/she 
meets the discharge criteria and will continue to be followed for safety, if possible. If the subject 
DMID Protocol 17-[ADDRESS_533892] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533893] will remain in  the study until symptoms resolve and he/she meets the 
discharge criteria , and will continue to be followed for safety, if possible . Subjects who refuse to 
drink any of the inoculum, and do not ingest any part of the inoculum, may be discharged 
immediately.  
Subjects will be directly observed at the time of dosing by a member of the clinical research 
team who is licensed to administer the study product. Administration will be documented in the subject’s  source document and entered  into the eCRF.  
7.2 Laboratory Evaluations  
Clinical Laboratory Evaluations  
Safety laboratory evaluations will be performed by [CONTACT_422738].  
Clinical safety lab testing will include hematology, chemistry and urinalysis. For baseline 
laboratory results that are abnormal according to the local laboratory reference range and fall 
within Grade 1 toxicity table range, these will not be considered exclusionary is determined by 
[CONTACT_11755].  
• Hematology: white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin (Hgb), and platelet count  
• Chemistry: sodium, potassium, creatinine , ALT , and total bilirubin  
A low creatinine value, a low total bilirubin value, and/or a low ALT value are/is acceptable for study inclusion. No lower limits of lab values for creatinine, total bilirubin, and ALT  are 
considered to be clinically significant.  
Urinalysis by [CONTACT_124764]. At screening, a result greater than trace protein will make the 
subject ineligible for study participation. Any other parameters on the dipstick having a positive result are not exclusionary and the decision to enroll the subject is at the discretion of the 
investigat or.   
Urine screening for opi[INVESTIGATOR_422691]. Any subject testing  positive for urine opi[INVESTIGATOR_422693].  
Urine pregnancy testing and urine dipstick will be performed in the clinic by a qualified study 
team member using a commercially available test.  
DMID Protocol 17-[ADDRESS_533894] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533895] will be immediately escorted out of the 
challenge unit.  
Research Assays  
Special assays described below will be performed in the research laboratories of the performance 
site. The details of type of samples and sample collection time are described in the Appendix A . 
Blood volumes for the study are listed in Table 1: Veni puncture/Blood Volumes (mL) .  
Phenotypic   
The secretor status of individual subjects will be determined based on the detection of histo -
blood group antigens (HBGAs) for the secretor antigens (Le b, Le y, H types) vs. the non-
secretor antigens (Le a and Le x) in their saliva. In this assay, boiled human saliva samples are 
diluted and used to coat wells of a 96- well EIA (Enzyme Immunosorbent Assay) plate in 
duplicate. The HBGAs present in a sample are determined by [CONTACT_183190] a panel of monoclonal antibodies specific to each individual HBGA. A set of saliva samples with known HBGA profiles are used as positive and negative controls, including at least one positive and one 
negative control sample for each assay. An OD result >0.2 obtained after application of 
horseradish peroxidase ( HRP ) conjugated anti-mouse antibody of the correct isotope determines 
if a sample is positive for a particular HBGA.  
Detection of Serum Norovirus IgG and IgA by [CONTACT_422739]  
96-well microtiter plates  are coated with rabbit antibody specific to noroviruses for overnight at 
4
oC. Following a wash, the plates are blocked with 5% nonfat dry milk. P urified GII.4 Norovirus 
P-particles ( PP) are then added. After incubation [ADDRESS_533896] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           65 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 solution is added to each well followed by [CONTACT_270652]. The reaction is 
stopped by [CONTACT_1121] 1M Phosphoric Acid. Plates are read using an EIA spectra reader (at a 
wavelength of 450 nm according to manufacturer’s instructions). All assays will include positive and negative control serum.  
Detection of Serum Norovirus Blocking  Antibody  by [CONTACT_422740] a 
potential “neutralization” test by [CONTACT_422741] P-particle binding to variable HBGAs. Briefly, saliva samples from individuals with k nown HBGA types or 
oligosaccharides representing different HBGAs will be coated on microtiter plates. The test 
antibodies (subject serum samples)  will be incubated with P -particles in separate plates at 37 °C 
for one hour before being transferred to the test plates. The bound P- particles will be measured 
by a guinea pig antibody specific to noroviruses followed by [CONTACT_422742]-conjugated goat anti-
guinea pig antibody following the same procedures described above. The highest dilution of the 
testing antibodies with  50% or 90% reduction of binding signals in comparison with controls 
without blocking will be used as the blocking titer for each sample.   
qRT- PCR (Real -time RT -PCR) for Quantitation of Norovirus RNA in stool  
This method will be the primary method for norovirus detection in the stool. Stool suspensions 
(10% w/v) will be prepared in sterile water. Viral RNA will be purified from the clarified extracts using the QiaAmp Viral Mini kit (Qiagen) according to the manufacturer’s instructions. 
The viral RNA will be eluted in a final volume of 60ul. Each sample will be tested using the 
TaqMan Fast Virus 1 -Step Master Mix (Applied Biosystems) with forward primer – QNIF2d 
5’ATG TTC AGR TGG ATG AGR TTC TCW GA, reverse prime r – Cog2R 5’TCG ACG CCA 
TCT TCA TTC ACA, and probe RING2 5’[ADDRESS_533897] Real- time PCR System 
(Applied Biosystems). Genome copi[INVESTIGATOR_422694] a standard Norovirus GII.4.  
Norovirus GII.4-  specific  Memory B Assay- The  memory B cell assay will be performed on 
frozen PBMC cells. PBMCs will be placed under in vitro polyclonal stimulation with mitogen 
for 6 days prior to addition to norovirus GII.4 P- particle coated plates (CIN -3; Virus Batch #01-
16C3).  Bound antibodies will be detected by [CONTACT_422743] a biotinylated anti-Ig 
antibody followed by [CONTACT_28745]-conjugated Streptavidin. The assay is developed by [CONTACT_1121] a precipi[INVESTIGATOR_422695]. The number of memory B cells per [ADDRESS_533898] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           66 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Antibody Secreting Cells (ASC) and Antibody in Lymphocyte Supernatant (ALS)   
At times specified in the protocol and the MOP, the peripheral blood mononuclear cells 
(PBMCs) will be isolated from whole blood and cryopreserved to be used in ASC and ALS 
assays. An ELISPOT will be used to enumerate Norovirus CIN- 3 specific IgA and IgG ASCs per  
total IgA and IgG ASCs . The ALS assay will measure by [CONTACT_422744]-
specific antibodies in cultures of PBMCs.  
Future Studies   
Stool and blood, specimens will be preserved for future use . Details of assays, methodology and 
location of testing will be determined at a later date.  
Additional innate and adaptive immunity assays: RNA, Protein (cytokine), and Cellular 
assays 
RNA assay:  W hole blood will be collected into PAXgene tubes. Samples will be remained at 
room temperature for 2 hours, moved to – 20 °C for 2h hours, and then transferred to  a 
temperature controlled and continuously monitored freezer at <-60 °C for longer- term storage. 
Total RNA will be then extracted and used for RNA -seq analysis to identify molecular signatures 
either at baseline or induced early after norovirus challenge that correlate with and predict 
norovirus illness, infection, and/or a daptive immune responses. 
Protein (Cytokine) assay : P lasma will be saved at PBMC processing for inflammation markers/ 
Luminex assay using commercially available kits . Depending upon the results from the RNA- seq 
analysis, various cytokines may be tested or obtained from commercially available sources.  
Cellular Assays : PBMCs will be collected, processed and stored at CCHMC in liquid N 2 vapor 
phase until used for phenotypi[INVESTIGATOR_422696] (APC) and NK cells. Further assays 
details are as described below:  
Assay for frequency and phenotype of APCs. A panel of BDCA- 1+ myeloid dendritic cells 
(mDC), cross -presenting CD141+ mDC, plasmacytoid DCs (pDC) as well as the pro-
inflammatory subset of CD14+CD16+ monocytes will be analyzed. Subsets of APCs and monocytes for activation phenotype using the CD80, CD83, CD86 and CCR7 surface markers 
will also be detected.  
Assay for frequency and activation status of NK cells:  CD16+CD56+ NK cells and CD4+ and 
CD8+ T cells will be assessed by [CONTACT_398]69 and HLA -DR and CD38 surface marker staining. 
DMID Protocol 17-[ADDRESS_533899] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           67 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Mucosal homing:  α4β7 will be detected on the surfaces of challenge -induced P- particle B cells 
and P- particle T cells.  
CIN-3; Virus Batch #01-16C3- specific and cross reactive T cell response will be assessed by 
[CONTACT_15242] (ICS) analyzed with multicolor flow cytometry. PBMCs will be 
activated ex vivo with P- particles  and brefeldin A (a protein transport inhibitor) will be added to 
retain the cytokines within the cells. After staining of cell surface with anti CD3/CD4/CD8 
antibodies, cells are then fixed in paraformaldehyde and permeabilized. A panel of anti - cytokine 
antibodies (IFNg/IL2/IL13/IL17/IL21) will then be used to measure TH1/TH2/TH17/TH21 responses generated by [CONTACT_422745] -3; Virus Batch #01-16C3 infection. 
Stool Collection for cytokine levels   
Cytokine levels will be determined by [CONTACT_954].  
Innate immune responses of PBMC -derived DCs against NoVs   
Peripheral blood mononuclear cells (PBMCs) isolated from subjects before challenge with NoVs 
will be studied for induction of dendritic cells (DCs) following stimulation with human 
granulocyte/macrophage colony stimulating factor (GM- CSF) and Interleukin -4 (IL -4). DCs will 
be analyzed phenotypi[INVESTIGATOR_422697].  
Adaptive Immune Responses in NoV Infected Individuals  
Functional analysis of P- particle specific T cells (production of cytokines such as interleukin-2, 
interferon -γ and tumor necrosis factor -α, etc.) will be performed by [CONTACT_422746]4
+ or CD8+ T cell epi[INVESTIGATOR_422698] .  
Characterization of Gut Microbiome  
Total Deoxyribonucleic Acid (DNA)  will be isolated from stool specimens using the NucliSENS 
EasyMag automated nucleic acid extraction system (BioMerieux).  16s rRNA sequences will be 
amplified by [CONTACT_422747] a universal primer set that detects all bacterial 
species. The resulting amplicons will be sequenced using next generation sequencing systems.  
 Laboratory Specimen Preparation, Handling, and Storage 
Whole blood will be collected by [CONTACT_422748]. Depending on the testing performed, aliquots of blood will be sent to the CCHMC Clinical Laboratory and/or the Laboratory for Specialized Clinical Studies, Division of Infectious Diseases, Cincinnati Children’s Hospi[INVESTIGATOR_422699]. 
DMID Protocol 17-[ADDRESS_533900] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533901] isolation procedures to minimize their risk of handling the 
stool specimens. If visible spi[INVESTIGATOR_422700] e stool container, the container 
will be wiped with an appropriate disinfectant and dried prior to the study labels being placed on the tubes. Any spi[INVESTIGATOR_422701]. The samples will then be placed in sealed specimen bags and sent to the Laboratory for Specialized Clinical Studies, 
Division of Infectious Diseases, Cincinnati Children’s Hospi[INVESTIGATOR_230401], for processing and storage until testing is performed. Instructions for Specimen Preparation, Handling, and Storage Instructions for specimen preparation, handling, and storage are included in the protocol- specific MOP. Instructions for specimen shipment are included in the protocol.  
 Laboratory Specimen Shippi[INVESTIGATOR_422702], Handling, and Storage Instructions for specimen preparation, handling, and storage are included in the protocol -specific MOP. Instructions for 
specimen shipment are included in the protocol- specific MOP.  
 
DMID Protocol 17-[ADDRESS_533902] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           69 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 8 ASSESSMENT OF SAFETY  
8.1 Assessing and Recording Safety Parameters  
 Adverse Event s (AEs)    
ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. FDA defines an AE as any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of medicinal (investigational) 
product. The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study monitor.  
AEs, including solicited systemic (subjective and quantitative) reactions , will be captured on the 
appropriate data collection form and eCRF.  Information to be collected for unsolicited non-
serious A Es includes event description, date of onset, assessment of severity , relationship to 
study product and alternate etiology  (assessed only by [CONTACT_31278] a diagnosis and listed on the Form FDA 1572 as an investigator), date of resolution , 
seriousness and outcome. AEs occurring du ring the trial collection and reporting period will be 
documented appropriately regardless of relationship. AE s will be followed through resolution.  
Any medical condition that is present at the time that the subjec t is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases, it should be recorded as an AE. 
If an event meets both the criteria of a study endpoint and an adverse event, the event only will 
be reported as a study endpoint. 
All A Es (laboratory and clinical symptoms) will be graded for severity and assessed for 
relationship to norovirus (see definitions). A Es characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865]. The start and stop date of each reported 
AE will be recorded on the appropriate data collection form and eCRF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of 
intensity.  
DMID Protocol 17-[ADDRESS_533903] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           70 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Severity of Event:   
All A Es (laboratory and clinical symptoms) will be assessed by [CONTACT_55296] a protocol-
defined grading system. For events not included in the protocol-defined grading system, the 
following guidelines will be used to quantify severity: 
• M ild (Grade 1) : Events that are usually transient and may require only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the subject’s 
usual activities of daily living.  
• Moderate (Grade 2) :  Events that are usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject. 
• Severe (Grade 3) :
  Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.   
Relationship to Study Products : 
   
The assessment of the relationship of an AE to the administration of study product is made only 
by [CONTACT_8703] a diagnosis and listed on the Form FDA [ADDRESS_533904]. To help assess, the following 
guidelines are used. 
• R elated  – There is a reasonable possibility that the study product caused the adverse 
event. Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study product and the adverse event.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the eve nt. 
DMID Protocol 17-[ADDRESS_533905] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533906]. Subjects will be assessed for solicited adverse 
events following challenge administration and will complete a n illness/ solicited adverse events 
memory aid to record symptoms for five days after discharge from the isolation facility . Subjects 
will also be asked to report  any unsolicited adverse events through Day [ADDRESS_533907] the presence and severity , headache, nausea, vomiting, 
abdominal cramps /discomfort/pain , abdominal gurgling, abdominal bloating, myalgia, 
malaise/fatigue, anorexia /loss of appetite,  and chills. The subjects will be provided with a 
thermometer. Any symptoms still present after Study Day 10 will continue to be followed until resolution  or determined to be stable per investigator discretion .   
Subjects will also be asked to report any medications taken  for approximately 30 days following 
NoV challenge administration  and any A Es including any emergency room or other medical 
visits (other than routine check -ups). The subject illness/solicited adverse events and unsolicited 
adverse event(s) memory aid s will be reviewed with the subject at subsequent visits. Illness and 
solicited adverse even ts will be analyzed using Appendix E . 
Severity of solicited adverse events will be graded according to Appendix E : Solicited Adverse 
Events Grading Scale. 
 
 Serious Adverse Events (SAEs)  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator or sponsor, it results in any of the following outcomes:  
• death  
• a life -threatening adverse event  
• inpatient hospi[INVESTIGATOR_1081] (excluding any 
extended stay during challenge admission due to continued vomiting, diarrhea, etc.)  
• a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or  
• a congenital anomaly/birth defect   
DMID Protocol 17-[ADDRESS_533908] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533909] and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
Life-threatening adverse event. An adverse event is considered “life- threatening” if, in the view 
of either the site principal investigator [INVESTIGATOR_10157], its occurrence places the patient or subject at 
immediate risk of death. It does not include an adverse event, had it occurred in a more severe 
form, might have caused death.  
SAEs will be : 
Assessed for severity and relationship to study product and alternate etiology  (if not related to 
study product) by a licensed study physician listed on the Form FDA 1572 or by [CONTACT_422749] [INVESTIGATOR_54720] -Investigator.  
Recorded on the appropriate SAE data collection form and eCRF . 
Followed through resolution by a licensed study physician (for IND studies, a physician listed on the Form FDA 1572 as the site Principal Investigator [INVESTIGATOR_54720]- Investigator).  
Reviewed and evaluated by [CONTACT_202421] (ISM) (as deemed necessary), the SMC  (periodic review unless related), DMID, and the IRB.  
 
 New- Onset Chronic Medical Conditions (NOCMCs)  
NOCMCs are defined as any new ICD -[ADDRESS_533910] 3 
months and requires continued health care intervention.  NOCMCs will be:  
Assessed for severity and relationship to study product and alternate etiology  (if not related to 
study product) by a licensed study physician listed on the Form FDA [ADDRESS_533911] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           73 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Recorded on the appropriate data collection form and eCRF . 
Followed through resolution by a licensed study physician (for IND studies, a physician listed on 
the Form FDA 1572 as the site Principal Investigator [INVESTIGATOR_54720]- Investigator).  
Reviewed and evaluated by [CONTACT_202421] (ISM) (as deemed necessary), the SMC  (periodic review unless related), DMID, and the IRB.  
 
8.2 Specification of Safety Parameters  
Safety will be based on the frequency and severity of non-norovirus challenge- related serious 
adverse events occurring throughout the course of the study. 
Solicited Adverse Events – solicited/anticipated events following challenge administration.  
Unsolicited Adverse Events - non- Norovirus challenge -related non-serious events occurring 
during 30 days following challenge administration. 
Clinical safety laboratory adverse events to include  WBC, absolute neutrophil count, 
hemoglobin, platelet count, potassium, sodium, creatinine, ALT and total bilirubin.  
Safety will be assessed by [CONTACT_422750]/SAEs 
(laboratory and clinical symptoms) in each group. A Safety Monitoring Committee (SMC) will 
be convened to review subject  safety data which may include solicited and unsolicited AE/SAEs, 
concomitant medications, clinical laboratory values and any physical examinations. Safety data 
will be reviewed by [CONTACT_422751].  
The study Sponsor may interrupt study dosing and/or study entry at any time if medically 
indicated. To minimize risk, the study enrollment and dosing will be stopped, and the safety data 
will be reviewed by [CONTACT_4484], if any of the following Halting Rules has been met . 
8.[ADDRESS_533912] challenge. 
New-Onset Chron ic Medical Co nditions (NOC MCs) will be collected from Day [ADDRESS_533913] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533914] be submitted immediately 
(within 24  hours of site awareness) on an SAE form to the CCHMC IRB as well as other 
required reporting agencies.  
 Reporting Serious Adverse Events 
SAEs will be followed until resolution even if this extends beyond the study-reporting period.  
Resolution of an AE is defined as the return to pretreatment status or stabilization of the condition with the expectation that it will remain chronic.  
Any AE that meets a protocol- defined serious criterion must be submitted immediately (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the 
following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_533915]. Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line: 1 -800- 537-9979 (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393] 
In addition to the SAE form, select SAE data fields must also be entered into the DCC system (for example : Advantage eClinical
®). Please see the protocol -specific MOP for details regarding 
this procedure.  
Other supporting documentation of the event may be requested by [CONTACT_154385].  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group. The DMID Medical Monitor and DMID Clinical Project Manager will be notified of the SAE by [CONTACT_422752].  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct. 
DMID Protocol 17-[ADDRESS_533916] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533917], the site 
principal investigator [INVESTIGATOR_29353]- investigator will report the event to the DMID 
Pharmacovigilance Group. 
 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the investigator, DMID, the Investigational New Drug (IND) 
sponsor, will report any suspected adverse reaction that is both serious and unexpected. DMID 
will report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event. DMID will notify FDA and all participating investigators (i.e., all investigators to whom the sponsor is providing drug under its IND(s) or under any principal investigato r’s IND(s)) in an IND safety report of potential serious 
risks from clinical trials or any other source, as soon as possible, but in no case later than [ADDRESS_533918] ion as soon as possible, but in no case later than 7 calendar 
days after the sponsor’s initial receipt of the information. Relevant follow up information to an IND safety report will be submitted as soon as the information is available. Upon request from 
FDA, DMID will submit to FDA any additional data or information that the agency deems 
necessary, as soon as possible, but in no case later than [ADDRESS_533919].  
All serious events designated as “not related” to study product(s), will be reported to the FDA at least annually in a summary format. 
 Regulatory Reporting for Studies Not Conducted Under DMID -Sponsored IND  
Following notification from the investigator, the IND sponsor will report events that are both 
serious and unexpected that are related to study product(s) to the FDA within the required 
timelines as specified in 21 CFR Part 312.32: fatal and life -threateni ng events within 7 calendar 
days (by [CONTACT_12221]). All written reports will be sent to the FDA within 15 calendar days.  All serious events designated as “not related” to study product(s), will be reported to the FDA at least annually in a summary for mat. 
 Reporting of Pregnancy  
Pregnancies occurring in study subjects will be reported in IDES. With the subject’s permission all study mandated venous blood samples will be collected and the subject will continue in 
DMID Protocol 17-[ADDRESS_533920] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533921]’s permission. 
8.[ADDRESS_533922] Values or Abnormal Clinical Findings  
The site principal investigator [INVESTIGATOR_29353] -investigator is responsible for recording all 
AE/SAEs that are observed or reported during this trial, regardless of the relationship to study 
product. AE/SAEs, abnormal laboratory test values, or abnormal clinical findings will be collected, assessed, documented, reported, and followed appropriately. 
For baseline laboratory results that are abnormal according to the local laboratory reference 
range and fall within Grade 1 toxicity table range, these will not be considered laboratory 
adverse event (AE) and will thus not be graded. However, if baseline c linical labs fall within 
Grade 1 range, then a laboratory AE is reported only if the value changes such that it falls into Grade 2 or higher when subsequent safety laboratory testing is done. 
8.6 Halting Rules 
 Study Halting Criteria  
DMID, the study Sponsor, may interrupt study dosing and/or study entry at any time if medically indicated. No additional subjects will be dosed until safety review has been completed. To minimize risk, the study enrollment and dosing will be stopped and the safety data will be 
reviewed by [CONTACT_4484], if any of the following Halting Rules have been met at any time 
throughout the study:  
DMID Protocol 17-[ADDRESS_533923] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533924]. 
2. Any Grade 3 or higher adverse event (of the same type, per MedDRA Preferred Term or 
parameter , excluding diarrhea, vomiting, nausea , abdominal crampi[INVESTIGATOR_007]/discomfort , and 
other solicited adverse events listed in section 8.1.2 as th ese are expected) in two 
subjects.  
The objective of the SMC is to decide if the study should continue per protocol, proceed with 
caution, be further investigated, be discontinued, or be modified and then proceed. Suspension of 
enrollment (for a particular group or for the entire study) is another potential outcome of a safety 
review.  
Upon completion of this review and receipt of the SMC recommendation, DMID will determine 
if study entry or study dosing should be interrupted or if study entry and study dosing may 
continue according to the protocol.  
The study may also be suspended because of safety findings such as an overall pattern of symptomatic, clinical, or laboratory events that the Medical Monitor considers related to study 
product and that may appear minor in terms of individual events, but that may collectively 
represent a serious potential concern for safety . 
8.7 Safety Oversight (ISM  plus SMC)  
 Independent Safety Monitor (ISM)  
An Independent Safety Monitor will be appointed to this study. Independent Safety Monitors are physicians with relevant expertise and whose primary responsibility is to provide timely independent safety monitoring. An ISM is assigned to each study site, is in close proximity to the study site and has the authority to readily access study subject records. The ISM reviews any 
SAE that occurs at the study site in real time and provides an assessment to the IND sponsor.  
 Safety Monitoring Committee (SMC) 
This clinical study will utilize an SMC, which is an independent group of experts that advises the DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is external to the DMID and comprises at least [ADDRESS_533925] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533926] planned meetings at the following time points:  
• Before study initiation  
• After each  challenge cohort has been completed   
• Ad hoc when a halting rule is met or as needed  
• At least annually  
If an Ad hoc meeting were convened, the SMC may be asked to review solicited and unsolicited AE/SAEs, concomitant medications, clinical laboratory values and any physical examinations. Safety data will be reviewed by [CONTACT_422751].  
Final review meeting: [ADDRESS_533927] summary format. The SMC may be asked to provide recommendations in response to questions posed by [CONTACT_308062]. 
Procedures for SMC reviews/meetings will be defined in a charter. The SMC will review 
applicable data to include but not limited to enrollment, demographic, dosing, laboratory and safety data which may include solicited and unsolicited AE/SAEs, concomitant medications, 
clinical laboratory values and any physical examinations. Safety data will be reviewed by [CONTACT_422753]. As an outcome of each review/meeting, the SMC will make a recommendation as to the advisability to continue,  modify or terminate the study. 
The IND sponsor or the SMC chair may convene the SMC on an ad hoc basis according to protocol criteria or if there are immediate concerns regarding observations during the course of the study. The Medical Monitor is empowered to stop study enrollment and/or study procedures if adverse events that meet the halting criteria are reported. The Medical monitor and the ISM will be responsible for reviewing SAEs in real time. The SMC will review SAEs on a regular basis and ad hoc during the study.  
DMID Protocol 17-[ADDRESS_533928] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533929]/Independent Ethics Committee 
Each site principal investigator [INVESTIGATOR_270598]/her research site(s) and send supporting documentation to the DMID before initiating recruitment of subjects. The investigator will submit applicable information to the IRB/IEC on which it relies for the review, to conduct the review in accordance with 45 CFR 46, ICH E6 
GCP, and as applicable, 21 CFR 56 (Institutional Review Boards) and 21 CFR 50 (Protection of 
Human Subjects) , other federal, state, and local regulations. The  IRB/IEC must be registered 
with OHRP as applicable to the research. DMID  must receive the documentation that verifies 
IRB/IEC -approval for this protocol, associated informed consent documents, and upon request 
any recruitment material and handouts or surveys intended for the subjects, prior to the 
recruitment and enrollment of subjects.     
Any amendments to the protocol or consent materials will be approved by [CONTACT_1201]/IEC before 
they are implemented. IRB/IEC review and approval will occur at least annually throughout the enrollment and follow -up of subjects and may cease if annual review is no longer required by 
[CONTACT_12229]/IEC. The investigator will notify the IRB/IEC of deviations 
from the protocol and reportable SAEs, as applicable to the IRB/IEC policy.  
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by [CONTACT_28820] (OHRP) for federally funded research.  
9.2 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. Before any study procedures are performed, informed consent will be obtained and docum ented. Subjects will receive a 
concise and focused presentation of key information about the clinical trial, verbally and with a consent form. The explanation will be organized and presented in lay terminology and language 
that facilitates understanding wh y one might or might not want to participate.  
An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
risks and discomforts, any expected benefits to the subject , and alternative treatment will be 
presented first to the subject.   
DMID Protocol 17-[ADDRESS_533930] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           80 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Subjects will also receive an explanation that the trial involves research, and a detailed summary 
of the proposed study procedures and study interventions/products. This will include aspects of 
the trial that are experimental, the probability for random assignment to treatment groups, any 
expected benefits, all possible risks (including a statement that the particular treatment or procedure may involve risks to the subject or to the em bryo or fetus, if the subject is or may 
become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in the trial, alternative procedures that may be available and the important potential 
benefits and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes available that may be relevant to their willingness to continue participation in the trial. Subjects will receive an explanation as to whether any compensation a nd any medical treatments are 
available if injury occurs, and, if so, what they consist of, or where further information may be obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payments, if any, to the subject for participating in the trial. They will be informed of whom to contact (e.g., the investigator) for answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may be terminated. The subjects will be informed that 
participation is voluntary and that they are free to withdraw from the stu dy for any reason at any 
time without penalty or loss of benefits to which the subject is otherwise entitled.   
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. The sponsoring company 
and the participant’s personal health care provider may review parts of participant records.  
Subjects will be informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory 
authority(ies) will be granted direct access to the subject’s original medical records for verification of clinical trial procedures and/or data without violating the confidentiality of the subject, to the extent permitted by [CONTACT_4913], and that, by [CONTACT_422754], the subject is authorizing such access.  
Subjects will be informed that records identifying the subject will be kept confidential, and, to 
the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available and, if the results of the trial are published, the subjec t’s identity will remain 
confidential. Subjects will be informed whether private information collected from this research and/or specimens will be used for additional research, even if identifiers are removed.   
DMID Protocol 17-[ADDRESS_533931] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533932](s) for their 
records. The subject(s) may withdraw consent at any time throughout the course of the trial. The rights and welfare of the subject(s) will be protected by [CONTACT_34693].  
Study personnel may employ recruitment efforts prior to obtaining study consent if a patient-specific screening consent is on record or if the IRB has agreed that chart review is allowed without a fully executed screening consent. In cases where there is n ot a patient- specific 
screening consent on record, site c linical staff may pre- screen via chart review and refer potential 
subjects to the Research staff. Research staff would obtain consent per the standard informed consent process before conducting protocol- specific screening activities.  
New information will be communicated by [CONTACT_16541] [INVESTIGATOR_422703]. The informed consent document will be updated, and subjects will be re- consented per IRB requirements, if necessary. Subjects 
will be given a copy of all informed consent forms that they sign.  
9.[ADDRESS_533933] other viruses  or bacteria. These residual clinical 
samples will be stored indefinitely at a central clinical storage facility and may be shared with investigators at the participating site and with other investigators at other institutions.  
Residual clinical samples will be available upon the completion of the study; however, future use 
clinical samples may be requested from DMID and shipped from the DMID CAR at any time.  
The samples will not be sold or used directly for production of any commercial product. Each 
sample will be encoded (labeled) only with a barcode and a unique tracking number to protect subject confidentiality. 
DMID Protocol 17-[ADDRESS_533934] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           82 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 There are no benefits to subjects in the collection, storage and subsequent use of their specimens 
for future research. Reports about future research done with subjects’ samples will NOT be kept 
in their health records.  
Subjects enrolled into the study will have their samples saved to be used for future research.  
Each sample will be encoded (labeled) only with a barcode and a unique tracking number to protect subject’s confidentiality. There are no benefits to subjects in the collection, storage and 
subsequent research use of specimens. Reports about future research done with subject’s samples 
will not be kept in their health records.  
Future Use of Stored Specimens  
Residual samples are those that are left over after the study has been completed and are stored 
for possible use in future research studies. Future use samples are extra tube/s of blood collected 
and stored for possible use in future research studies. Retention of residual and future use samples and the potential for use in future research studies will be a condition of study participation. Subjects who sign the informed consent form for the study are consenting to allow the collection, storage and use of a ny residual sa mples (serum or cells derived from venous blood 
samples) or future use samples for possible use in future research studies,  such as examining 
additional immunological assessments or testing for antibodies against other viruses or bacteria.  
Residual and future use samples will be encoded with a barcode label and unique tracking number to protect subject identity. Samples will be stored indefinitely at a DMID designated 
central storage facility. Residual samples may be shared for purposes other than per protocol 
analysis with investigators at participating VTEU sites and with investigators at other institutions once the clinical study report has been finalized. Future use research samples may be requested from DMID and shipped from the DMID CMS  at any time.  
Residual and future use samples will not be sold or used directly for production of any commercial product . Genetic tests may be performed on samples. There are no benefits to 
subjects in the collection, storage and subsequent use of their specimens for future research. Reports about future research done with subjects’ samples will NOT be kept in their health 
records.  
Subjects may withdraw consent for study participation at any time by [CONTACT_422755]. However, any data from sample(s) collected prior to the withdrawn consent will not be removed including genomic data. There will be no further use of 
residual samples or collection and use of future use samples after consent has been withdrawn.  
DMID Protocol 17-[ADDRESS_533935] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           83 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 9.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will be inclusive of all adults who meet the Subject Inclusion Criteria (see Section 
5.1.1) and do not meet the Subject Exclusion Criteria ( see Section 5.1.2 ), regardless of religion, 
sex, or ethnic background. Non- English speakers will be excluded from this protocol as it is 
medically necessary that the subjects are able to communicate fluently with the medical staff regarding acute medical changes. Should the outcome of this trial be deemed acceptable, additional trials may be initiated including those in other populations.  
Pregnant women will be excluded as it is unknown if the challenge poses risks to an unborn 
child.  Children are excluded due to the ethical considerations of not enrolling a child in a greater than minimal risk study unless there is a prospect for direct b enefit.  
 
9.[ADDRESS_533936] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
subject’s clinical information, and all other information generated during participation in the 
study. No information concerning the study, or the data generated from the study will be released to any unauthorized third party without prior written approval of the DMID and the subject. Subject confidentiality will be maintained when study results are published or discussed in conferences. The sponsoring company and the participant’s personal health care provider may 
review parts of participant records.  The study monitor, or other authorized representatives of the 
sponsor or governmental regulatory agencies may inspect all documents and records required to 
be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pha rmacy records for the subjects in this study. The clinical study site will permit 
access to such records.  
All records will be kept locked and all computer entry and networking programs will be carried out with coded numbers only and with password protected systems. All non- clinical specimens, 
evaluation forms, reports, and other records that leave the site will be identified only by a coded number. 
Each subject will be assigned a unique study identifier. All data collection sheets will identify the 
subject by a unique identifier, and the date. Names will not be used on any samples or in any publication of this study. All efforts will be made to prote ct the privacy of subjects. 
DMID Protocol 17-[ADDRESS_533937] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           84 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 This information and data will not be used by [CONTACT_16541] [INVESTIGATOR_422704]. These restrictions do not apply to: (1) 
information which becomes publicly available through no fault of  the site principal investigator [INVESTIGATOR_294989]; (2) information which is necessary to disclose in confidence to an IRB solely for the evaluation of the study; (3) information which it is necessary to disclose in order to provide appropriate medical care to a study subject; or (4) study results which may be published. 
9.[ADDRESS_533938]’s insurance or third party. Subjects may be compensated for their participation in this trial.   
Compensation will be in accordance with the local IRB’s policies and procedures, and subject to IRB approval. 
If it is determined by [CONTACT_16541] [INVESTIGATOR_122767] a subject as a direct 
result of the tests or treatments that are done for this trial, then referrals to appropriate health care facilities will be provided to the subject. Study personnel will try to reduce, control, and treat any 
complications from this trial. Immediate medical treatment may be provided by [CONTACT_202445]. No financial compensation will be provided to the subject by [CONTACT_122845], NIH to the subject, for any injury suffered due to participation in this trial.  
There is no cost to subjects for the research tests, procedures, and study product while taking part in this trial. Subjects may be compensated for their participation in this trial. Compensation will 
be in accordance with the local IRB’s policies and procedures, and subject to IRB approval. 
If it is determined by [CONTACT_16541] [INVESTIGATOR_122767] a subject as a direct 
result of the tests or treatments that are done for this trial, then referrals to appropriate health care facilities will be provided to the subject. Study personnel will try to reduce, control, and treat any complications from this trial. Immediate medical treatment may be provided by [CONTACT_202445]. No financial compensation will be provided to the subject by [CONTACT_122845], NIH to the subject, 
or by [CONTACT_319694]. 
DMID Protocol 17-[ADDRESS_533939] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           85 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 10 STATISTICAL CONSIDERATIONS  
10.1 Study Hypotheses 
This is a phase 1 dose-escalation study designed to determine the optimal dose of an 
experimental human norovirus GII.4 challenge strain to be used in future trials testing candidate vaccines and/or therapeutics. The trial is exploratory in nature and thus, is not designed to test a specific hypothesis. Rather , it is intended to estimate illness (and therefore, infection) rates for up 
to three different challenge doses and to evaluate the safety of the challenge strain.  
10.2 Sample Size Considerations  
The study will enroll up to 3 cohorts of approximately 16 subjects each, for a total of up to 48 
subjects, aged 18-49 years (inclusive). Each cohort will enroll [ADDRESS_533940] cohort will receive a dose of 3.5x10
3 copi[INVESTIGATOR_014]. 
Subsequent doses will be based on attainment of response rate > 50%. They will be smaller if the 
threshold of 50% is observed and will be larger if it is not observed. If the illness rate is >50% 
for this cohort then the final cohort will be tested at 3.5x101 copi[INVESTIGATOR_014], the lower bound of the range 
of consideration. 
The final row of the schema (Figure 1) indicates possible doses for future studies based on the 
re
sults of this study. It will not be sufficient to demonstrate a 50% response rate (8 /16) at the 
final dose as this yield s a confidence interval of ( 26% to 74%). A response rate of 72% (14/18) is 
required for  the lower bound of the 95% confidence interval to exclude 50% (1 4/18 implies a 
confidence interval of 52.3% to 93.6 %). 
Table [ADDRESS_533941] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           86 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
  Table 3. O bserved illness rates and 95% confidence intervals for a challenge dose group of   
N=18 secretor positive subjects.  
Number with illness  Observed Illness Rate  95% Exact CI  
0 0 (0.00, 0.19)  
2 0.11 (0.01, 0.35)  
4 0.22 (0.06, 0.48)  
6 0.33 (0.13, 0.59)  
8 0.44 (0.22, 0.69)  
10 0.56 (0.31, 0.78)  
12 0.67 (0.41, 0.87)  
14 0.78 (0.52, 0.94)  
16 0.89 (0.65, 0.9 9) 
18 1.00 (0.81, 1.00)  
 
10.3 Treatment Assignment Procedures 
 Randomization Procedures 
This is a non -randomized dose escalation study. Enrollment will be done online using the 
enrollment module of the Data Coordinating Center’s (DCC) Internet Data Entry System (IDES).  
Each cohort will be comprised of approximately 16 subjects (1 5 secretors and 1 non- secretors)  
who will receive the same dose of challenge product . Each cohort will have [ADDRESS_533942].    Instructions for use of the enrollment module will be included in the IDES User’s Guide. Manual 
back -up procedures and instructions are provided for use in the event that the site temporarily 
loses access to the Internet or the online enrollment system is unavailable.   
Per International Conference on Harmonisation (ICH) guideline E6: Good Clinical Practice 
(GCP), screening records will be kept at each participating clinical study site to document the reason why an individual was screened but failed trial entry criteria. The reasons why individuals failed screening will be recorded in IDES.  
DMID Protocol 17-[ADDRESS_533943] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           87 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 
 Masking Procedures  
An unblinded study member will review the “secretor” status of subjects and prepare a list of 
subjects to be admitted to the inpatient unit for challenge . The subjects, the study personnel who 
perform any study- related assessments, and laboratory personnel performing study assays will be 
blinded to secretor status.  
10.[ADDRESS_533944]  safety data, which may include solicited 
and unsolicited AE/SAEs, concomitant medications, clinical laboratory values, and any physical examinations. Safety data will be reviewed by [CONTACT_422756] 8.7 and per the SMC charter for this study. As an outcome of each review/meeting, the SMC will make a recommendation as to the advisability of proceeding with the next cohort, and to continue, modify, or terminate the study.  
 Interim Immunogenicity or Efficacy Review  
As part of the SMC review between cohorts, the number of subjects who achieve illness will be presented in order to determine which dose to administer in the following cohort.                             
An interim immunogenicity review  will be performed after the second cohort to determine if 
there is a correlation between anti - norovirus GII.4 serum IgG by [CONTACT_159335]/or blocking assay 
(protective antibody titers) and illness rate. If anti -norovirus GII.4 serum IgG by [CONTACT_159335]/or 
blocking assay correlates to incidence of illness, then the eligibility criteria will be revised for the 
final cohort to exclude people at low risk for norovirus infection.  
Summaries for these reviews will be included in the unblinded report prepared for the closed 
session of the SMC. No formal hypothesis testing will be performed.  
10.[ADDRESS_533945] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533946]. 
The modified intent- to-treat (mITT) population includes all subjects who received the challenge 
study product and contributed both pre- and at least one post-challenge sample during the 
inpatient period for which a conclusion can be made regarding illness and infectivity.  
The per protocol (PP) population includes all subjects in the mITT subset with the following 
exclu sions: 
• Data from all available visits for subjects found to be ineligible at baseline 
• Data from all available visits for subjects who do not ingest all of the inoculum 
• Data from all visits subsequent to protocol deviations, such as: 
o Receipt of non -study licensed live vaccine through Day 30 
o Long- term use ( >2 weeks) of high- dose oral ( >20 mg per day prednisone or 
equivalent) or parenteral glucocorticoids, or high- dose inhaled steroids for greater 
than [ADDRESS_533947] -
challenge 
• Data from any visit that occurs substantially out of window  
 Primary Objectives  
Determine the optimal challenge dose of Norovirus GII.4 CIN-3 Batch No.: 01-16C3 norovirus to achieve illness in ≥50% of subjects (illness is defined as norovirus infection determined by 
[CONTACT_422757] a) ≥3 loose or liquid stools in a 24 -hour per iod, b) >300 gm of loose or 
liquid stool in a 24-hour period c) and/or any epi[INVESTIGATOR_254962]), during the inpatient period.  
The primary objective of this study is to find the lowest dose of the GII.[ADDRESS_533948] a 50% illness rate in secretor positive subjects. The undiluted stock 
of the CIN -3 challenge strain is 3.5 x105 copi[INVESTIGATOR_014]/mL. Based on previous experience with this GII.[ADDRESS_533949] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533950] any formal hypothesis.   
The schematic in Figure 1 is intended to guide the selection of doses to be tested and the final 
dose to be adopted for future trials. It is based on the observation that in previous studies with 
CIN-1 the illness response rates were relatively “flat”. That is, a reduction in dose did not result 
in an equivalent reduction in response. Results in this trial may be inconsistent with this assumption and the proposed schema may be modified based on observed results. Unless 
explicitly stated , response rates will refer only to secretor positive subjects receiving an active 
challenge dose.  
A logistic regression model of responses as a function of log dose will be constructed  to select a 
recommended dose for future studies.  
The challenge results will also be described by [CONTACT_422758] (combining like doses) 
using descriptive statistics. In particular, point estimates and 95% confidence intervals will be computed. 
 Secondary Objectives  
Evaluate the safety of the Norovirus GII.4 CIN -3 Batch No.:01- 16C3 challenge strain  
Solicited events will be collected through Study Day 1 0 after virus challenge. These results will 
be summarized by [CONTACT_422759]’ maximum response for each solicited event category and for all categories combined. These results will be tabulated by [CONTACT_422760], moderate  or severe and examined for a dose-response relationship using logistic 
regression.  
Unsolicited events, in contrast to solicited events, will be based on subjects experiencing Grade 3 
adverse events after virus challenge that are not norovirus related. The rate of such AEs  is 
expected to be low. If this is the case then this data will be summarized using a listing of all 
events, including, but not necessarily limited to, a description of the event, the study cohort, challenge dose and timing of the event. If there are a suf ficient number of events they will be 
summarized by [CONTACT_422761].  
Determine the rate of infection at different challenge dose s by: 
• Detection of Norovirus GII.4 in the stool using specific qRT -PCR  
• Anti- Norovirus GII.4 serum IgG by [CONTACT_6428] (≥4- fold rise from baseline through Day 30) 
DMID Protocol 17-[ADDRESS_533951] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           90 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 The number and percentage of subjects with infection will be described by [CONTACT_422762] (combining like doses) using descriptive statistics. In particular, point estimates and 95% 
confidence intervals will be computed.  
A number of the secondary and exploratory objectives listed below will be summarized by 
[CONTACT_422763]. “Mean” should be understood to refer to the arithmetic mean or 
the geometric mean , as appropriate. The summary statistic will depend on the distribution of the 
particular parameter.  
Measure the severity of acute gastroenteritis.  
The modified Vesikari  scores will be summarized by [CONTACT_9318]. The 
distribution of the scores will be examined, transformations such as a log transformation may  be 
made, and appropriate point estimates and summary of variability will be provided. Scores will 
also be tested to examine if there is a relationship between Vesikari scores and challenge dose. 
The statistical method used (parametric or non -parametric) will depen d on the distribution of the 
scores.  The duration of vomiting and/or diarrhea (in hours) during the inpatient period will be 
calculated for each subject and summarized by [CONTACT_9318].  
Determine the quantity and duration of virus shedding in stool by [CONTACT_16641] -PCR  
PCR results will be summarized using estimates and 95% confidence limits for the percentage of subjects with positive stools, the mean duration (in days) of viral shedding , and the peak 
GEC/mL for each subject will be summarized. The results will be summarized for cohort and 
dose specific groups. Additionally, longitudinal methods may be used to explore the possibility 
of determining not just the presence of virus but to estimate trends in the magnitude of virus shed 
over time.  
 Exploratory Objectives 
Determine norovirus GII.4 –specific antibody responses at baseline, Day 15, and Day 30 
• Serum IgA and IgG by [CONTACT_6428]  
• Serum Blocking Antibody by [CONTACT_422764]- and post -challenge virus -specific ELISA assay measures will be summarized using the 
geometric mean fold rise and proportion of subjects with at least a 4-fold antibody response for 
each of the assays.  
DMID Protocol 17-[ADDRESS_533952] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           91 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Determine total and norovirus GII.4- specific Memory B cell response by [CONTACT_422765]- specific Memory B cells per 106 PBMC will be summarized  by 
[CONTACT_260653]/dose groups. 
 
Determine the effect of baseline norovirus antibody levels (serum IgG, IgA, and blocking 
antibody) on becoming infected with norovirus  
This objective will be addressed by [CONTACT_325227] a possible association between level of pre-existing antibodies, challenge dose and rates of illness or infection. These results will be examined graphically by [CONTACT_422766]-existing antibodies among infected (ill) and not infected (not ill) subjects within dose groups and across all dose groups. If there is 
any suggestion of a relationship between pre-existing antibody and response this will be modeled 
using logistic regression to estima te the relationship between infection (illness) rates and 
antibody level.  
Determine total and norovirus GII.[ADDRESS_533953] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           92 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 11 ELECTRONIC CASE REPORT FORMS  AND ACCESS 
TO SOURCE DATA/DOCUMENTS  
The participating VTEU site will maintain appropriate medical and research records in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the 
protection of confidentiality of subjects. Each site will permit authorized representatives of the 
DMID, its designees, and appropriate regulatory agencies to examine (and when required by [CONTACT_54003] l aw, to copy) clinical records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety and progress. T hese representatives will be permitted access to 
all source data and source documents  (paper and electronic) , which include, but are not limited 
to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_422705], microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, and subject files and records kept at the pharmacy, at th e laboratories, 
and medico- technical departments involved in the clinical trial. Source data are all information, 
original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
The study uses direct data entry for the participating clinic site and a web -based e- Memory aid  
for subjects. All eCRFs serve as the source documents. Subjects will be trained to use a database 
to complete a web based “e- Memory a id” and are expected to enter information in the e -Memory 
aid each day. Subjects using the e-Memory aid will also be provided a paper memory aid for 
their use in the event they are unable to access the web -based system. The subjects will be asked 
to enter the information from the pa per memory aid into the e -Memory aid once they are able to 
access the web -based system.  Web -based access can be provided to subjects while on site for 
study visits.  
Subjects will record temperature, systemic symptoms , and any new medications used following 
challenge through Study Day 10. Subjects will report any unsolicited adverse event through the 
[ADDRESS_533954] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533955] -entered data will be available for review by [CONTACT_422767].  
The site staff will be the data originators for the clinically reviewed data in Advantage eClinical® 
that will be used for the study endpoints. A list of all authorized site staff data originators will be included on the Study Personnel/Signature [CONTACT_122868]. 
DMID Protocol 17-[ADDRESS_533956] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           94 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 12 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each participating site and its 
subcontractors are responsible for conducting routine quality assurance (QA) and quality control 
(QC) activities to internally monitor study progress and protocol compliance. The site principal investigator [INVESTIGATOR_71464] -related sites, source data/ data collection forms, 
and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482]. The site principal investigator [INVESTIGATOR_422706].  
The DCC will implement quality control procedures beginning with the data entry system and generate data quality control checks that will be run on the database. Any missing data or data anomalies will be communicated to the participating site(s) for clarification and resolution.  
DMID- designated clinical monitors will verify that the clinical trial is conducted , and data are 
generated, documented (recorded), and reported in compliance with the protocol, ICH/GCP guidelines, and the applicable regulatory requirements. Clinical monitoring reports will be submitted to DMID.  
DMID Protocol 17-[ADDRESS_533957] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533958] enrolled in this study.   
The sponsor and/or its designee will provide guidance to the site principal investigators and other 
study personnel on making corrections to the data collection forms and e CRF.  
13.2 Data Coordinating Center/Biostatistician Responsibilities  
All electronic case report forms and laboratory reports must be reviewed by [CONTACT_422768], who will ensure that they are accurate and complete.  Adverse events must be recorded on the appropriate electronic case report form, as sessed for severity and relationship, 
and reviewed by [CONTACT_16541] [INVESTIGATOR_29353]- investigator.  
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site principal investigator. During the study, the site principal 
investigator [INVESTIGATOR_422707]. 
The S DCC for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data. 
13.3 Data Capture Methods  
Clinical (including, but not limited to, AE/SAEs, concomitant medications, medical history, physical assessments, and clinical laboratory values ), reactogenicity and immunogenicity data 
will be entered into eCRFs via a [ADDRESS_533959] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           96 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.  
Clinical data will be entered directly into electronic case report forms by [CONTACT_44518].  
13.4 Types of Data 
Data for this trial will include clinical, safety, and outcome measures (e.g., clinical assessments, 
clinical laboratory values, solicited events, and immunogenicity data).  
13.[ADDRESS_533960] for  the indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for the study product, until 2 years after the investigation is discontinued and the FDA has been notified. 
These documents will be retained for a longer period, however, if required by [CONTACT_427]. 
ICFs for future use will be maintained as long as the  sample/specimen exists.  
No records will be destroyed without the written consent of the sponsor. It is the responsibility of the sponsor to inform the site principal investigator [INVESTIGATOR_122774]. The participating VTEU sites must contact [CONTACT_422769] r authorization prior to the 
destruction of any study records. 
DMID Protocol 17-[ADDRESS_533961] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           97 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 14 CLINICAL MONITORING  
Site monitoring is conducted to ensure that the human subjects’ protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is conducted in accordance with the protocol, protocol- specific MOP and applicable sponsor 
standard operating procedures (SOPs) . DMID, the sponsoring agency, or its designee will 
conduct site-monitoring visits as detailed in the clinical monitoring plan. 
Site visits will be made at standard intervals as defined by [CONTACT_149098]. Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, eCRFs, informed consent forms , medical and laboratory 
reports, and protocol and GCP compliance. Site monitors will have access to each participating 
site, study personnel, and all study documentation according to the DMID- approved site 
monitoring plan. Study monitors will meet with site principal investigators to discuss any 
problems and actions to be taken and will document site visit findings and discussions. 
DMID Protocol 17-[ADDRESS_533962] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533963] submitted for them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic version of their final, peer- reviewed 
manuscripts upon acceptance for publicati on, to be made publicly available no later than [ADDRESS_533964] be 
accessible to the public on PubMed Central no later than 12 months after publication. 
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/ 
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm 
As of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_533965] applied for certification of delayed posting. 
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible party is DMID which will register the trial and post results.   
The responsible party DMID  to request certification of delayed posting. 
Refer to:  
• Public Law 110-85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-[ADDRESS_533966] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533967] Dis 2011;52:466-74. 2. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 
2009;361:1776-85. 3. Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008;80:1468-76. 4. Bok K, Parra GI, Mitra T, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A 2011;108:325-30. 5. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to 
Norwalk virus infection. Nat Med 2003;9:548- 53. 
6. Huang P, Farkas T, Zhong W, et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005;79:6714-22. 7. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005;79:2900-9. 8. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor -independent susceptibility pattern, Sweden. Emerg Infect 
Dis 2010;16:81-7. 9. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.[ADDRESS_533968] Dis 2012;206:1386-93. 10. Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015;211:870-8. 11. Atmar RL, Bernstein DI, Lyon GM, et al. Serological Correlates of Protection against a 
GII.4 Norovirus. Clin Vaccine Immunol 2015;22:923-9. 12. Adler JL, Zickl R. Winter vomiting disease. J Infect Dis 1969;119:668- 73. 
13. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008;14:1553-7. 14. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human 
Norwalk Virus illness. N Engl J Med 2011;365:2178-87. 15. Matthews JE, Dickey BW, Miller RD, et al. The epi[INVESTIGATOR_422708]: a review of risk factors associated with attack rate and genogroup. Epi[INVESTIGATOR_19277] 2012;140:1161-72. 
 
DMID Protocol 17-[ADDRESS_533969] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           100 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 17 APPENDICES 
Appendix A : Schedule of Events 
Appendix B : Toxicity  Table/Laboratory A dverse Event  Grading Scales 
Appendix C : Vital Signs ADVERSE Event Grading Scale 
Appendix D : Diarrhea/Vomiting Grading Scale 
Appendix E : Solicited Adverse Events Grading Scale 
Appendix F : Modified Vesikari Score 
  
DMID Protocol 17-[ADDRESS_533970] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           101 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 Appendix A: Schedule of Events  
 Outpatient  
Screening  Inpatient Challenge Admission Outpatient Follow -Up Final 
Study 
Contact  
[CONTACT_422770] -
60 to 
Day -2 
Visit 
00A $ Day 
-1 
Visit 
00B$ Day 
1 
Visit 
01 Day 
2 
Visit 
02 Day 
3 
Visit 
03 Day 
4 
Visit 
04 Day 
5* 
Visit 
05 Day 
6+2 
clinic  
visit  
Visit
06   Day 
15+/
-1  
clinic  
visit  
Visit 
07  Day  
30 
-
2/+5 
clinic  
visit  
Visit 
08   Day  
45+/
-5 
clinic  
visit  
Visit 
09   
 Day 
60+/
-5  
clinic  
visit  
 Visit 
10  Day 
180+/ -[ADDRESS_533971]  
visit  
Visit 11  
Informed Consent  X (X) (X)           
Test Of Understanding! X  (X) (X)           
Medical History/ 
(Demographics at screening)  X X (X)     X X X X X X 
Concomitant Medication 
History1 or Review  X X (X) X X X X X X X    
I/E Criteria Review  X X X           
Physical Examination 
(Abbreviated)  # X             
Clinical Assessment/Symptom 
Directed PE2  X X X X X X (X) (X) (X) (X) (X)  
Monitor/Record Fluid Input/Output (I/Os) 
=    X X X X       
Vital Signs3,4 X X X4 X X X X X (X) (X) (X) (X)  
Body Weight5 X X (X) (X) (X) (X) (X)       
Chemistry6, 8  X  (X) (X) (X) (X) (X)       
Hematology7, 8  X  (X) (X) (X) (X) (X)       
Urinalysis9 X  (X) (X) (X) (X) (X)       
Urine opi[INVESTIGATOR_422709]  X             
Urine or serum Pregnancy 
Test (females of childbearing 
potential )  X X  (X)           
DMID Protocol 17-[ADDRESS_533972] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533973]  
Study Day Day -
60 to 
Day -2 
Visit 
00A $ Day 
-1 
Visit 
00B$ Day 
1 
Visit 
01 Day 
2 
Visit 
02 Day 
3 
Visit 
03 Day 
4 
Visit 
04 Day 
5* 
Visit 
05 Day 
6+2 
clinic  
visit  
Visit
06   Day 
15+/
-1  
clinic  
visit  
Visit 
07  Day  
30 
-
2/+5 
clinic  
visit  
Visit 
08   Day  
45+/
-5 
clinic  
visit  
Visit 
09   
 Day 
60+/
-5  
clinic  
visit  
 Visit 
10  Day 
180+/ -[ADDRESS_533974]   X            
Serum norovirus  antibody (IgG, 
and IgA ELISA and blocking antibody)  X (X)      X X     
RNA seq assay (PAXgene ) 
Future Use   X (X) X  X  X X X    
Blood for cytokine by [CONTACT_422771] (plasma) Future Use   X (X) X  X  X X     
Blood for DC/NK (PBMC) 
Future Use   X (X) X  X  X X     
Norovirus GII.4 -specific 
Memory  B cells/ELISpot assay 
(PBMC)    X (X)       X  
  
X  
Norovirus GII.4 -specific T 
cell/intracellular cytokine assay 
(PBMC)  Future Use   X (X)     X X X     
Norovirus GII.4 -specific ASC 
ELISpot  and ALS ELISA   X (X)     X X     
Saliva for secretor status 10 
(phenotype)  X             
Stool collection system (“stool 
kit”) and instructions provided    X X X X X X X X X  
X   
DMID Protocol 17-[ADDRESS_533975] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           [ADDRESS_533976]  
Study Day Day -
60 to 
Day -2 
Visit 
00A $ Day 
-1 
Visit 
00B$ Day 
1 
Visit 
01 Day 
2 
Visit 
02 Day 
3 
Visit 
03 Day 
4 
Visit 
04 Day 
5* 
Visit 
05 Day 
6+2 
clinic  
visit  
Visit
06   Day 
15+/
-1  
clinic  
visit  
Visit 
07  Day  
30 
-
2/+5 
clinic  
visit  
Visit 
08   Day  
45+/
-5 
clinic  
visit  
Visit 
09   
 Day 
60+/
-5  
clinic  
visit  
 Visit 
10  Day 
180+/ -[ADDRESS_533977]  
visit  
Visit 11  
Fecal IgA (Future Use) *** ****   X (X) X  X  X X X    
Stool Collection for shedding 
of norovirus  PCR11, 12 □  X X X  X X X X X X X X□  
Stool Collection for 
microbiomes (Future Use)12****   X (X) X  X  X X X    
Stool Collection for cytokines (Future Use)
12   X (X) X  X  X X X    
Challenge Administration13   X           
Solicited Adverse Events  
Assessments     X X X X X       
Illness/ Solicited  Adverse 
Events  Memory Aids14^       X^ X^ X^ X^    
Adverse Event Monitoring15   X X X X X X X X X X X 
Discharge from Inpatient 
Facility  (if discharge criteria met )        X+       
. 
1.  On Day 1, confirm that the subject has not taken any prohibited medications prior to challenge. All 
concomitant medications taken in the [ADDRESS_533978] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           104 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 5.  Weight will be checke d at screen and baseline, prior to challenge. Weight will be obtained at other times as 
clinically indicated.      
6.  Serum chemistry parameters include alanine transaminase (ALT), total bilirubin, creatinine, potassium, 
sodium.  
7.  Hematology parameters include white blood cells (WBC) with neutrophils  (ANC), hemoglobin, and platelet 
count.  
8.  Screening labs (chemistry and hematology ) will be repeated if original labs obtained more than [ADDRESS_533979] clear liquids within 4 hours of challenge but  will be NPO (nothing by [CONTACT_1966]) for 90 minutes  
       before and for 90 minutes after challenge administration.  
14.  Subjects will complete a daily memory aid of illness/ solicited events  symptoms, changes in medical status, 
and concomitant medications. Subject’s memory aids will be reviewed at the Day [ADDRESS_533980] and retain the illness/ solicited events  memory aid at the Day 15 visit.  
15.  Adverse events will be collected to Day 30. Adverse events limited to new -onset chronic medical conditions 
and Serious Adverse Events will be collected up to Day 180.                                                                           
(X) Represents study related procedures that are not required but may  be done on this day, if indicated. (i.e. Subjects  
may be  admitted  the day before  challenge or on the  day of challenge. Some study related procedures may occur 
within 24 hours of challenge.) .  
* Subjects needing to remain past Day [ADDRESS_533981] study evaluations repeated daily until discharge.  
*** Efforts will be made to collect [ADDRESS_533982] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           105 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 15, 2018  
 ****Since fecal IgA stools will be sent to the Fisher Repository, and then microbiome samples can be sent to the 
repository as well. Samples may be collected together (with appropriate vials) as microbiome and fecal IgA 
samples for future use with appropriate collection days.  
□     Subjects who continue to shed Norovirus at the Day 60 visit will be followed for clearance.   
!! Subjects  will be provided with educational materials at screening and given complete education about study 
participation. A sample test may be given during the education process. If a subject  does not score a 70% on 
the exam, he/she may re -take the test.  
#     An abbreviated physical examination is distinguished from a complete physical exam in that all assessments are  
        not required (e.g. genito- urinary and rectal exams).  
 
=     All emesis will be measured . All stools will be graded for consistency (see Appendix D:     
       Diarrhea/Vomiting Grading Scale for details), and all loose or watery stools (i.e., those that conform to the    
       shape of the container)  also will be weighed . Subjects who develop diarrhea will be asked to drink 1.5 mL of  
       ORS for each gram of diarrheal stool that they produce. Subjects developi[INVESTIGATOR_422682] a   
       volume of ORS equivalent to the amount of the emesis.  
 $     Screening evaluations may occur over 1 or more visits . 
 
+     Subjects will be p rovide d instructions and “stool kit” to collect sample .  
@    Provide subject with  digital thermometer and instructions in its use and asked to take and record their oral 
temperature once daily at the same time each day for 5 days after discharge.  
^     Remind /review with subjects  to contact [CONTACT_422772] a household contact [CONTACT_422773] a week after being discharged from the inpatient unit.  
 
 
 
                                     
DMID Protocol 17-[ADDRESS_533983] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           106 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Appendix B: Toxicity Table/Laboratory Adverse Event Grading 
Scale  
Adverse Event Grading  
This protocol is CDISC compliant. During screening, subjects will have blood drawn to 
determine if any clinical laboratory abnormalities exist that would preclude study participation.  
Laboratory Mild  
(Grade 1) Moderate 
(Grade 2) Severe  
(Grade 3) 
Sodium, low, mEq/L  132 – 135 130 – 131 125 – 129 
Sodium, high, mEq/L  146 – 147 148 – 149 150 or greater  
Potassium, high, mEq/L  5.2 – 5.3 5.4 – 5.5 5.6 – 5.7 
Potassium, low, mEq/L  3.3 – 3.4 3.1 – 3.2 2.9 – 3.0 
Creatinine , high  mg/dL  (female)  1.0 - 1.1 1.2 - 2.0 2.1 – 2.5 
Creatinine , high  mg/dL (male)  1.2 – 1.3 1.4 – 2.0 2.1 – 2.5 
Liver Function Tests (ALT) 
increase by [CONTACT_12245]  >1.1-2.[ADDRESS_533984]  >2.5-5.[ADDRESS_533985]  >5.0x ULN 
Total bilirubin  >1.0-1.[ADDRESS_533986]  >1.5-2.[ADDRESS_533987]  >2.[ADDRESS_533988]  
Hgb (female), low g/dL  10.9-11.6 9.4 – 10.8 <9.3 
Hgb (male), low g/dL  13.1-13.2 12.5-13.0 <12.4 
WBC, increase, cells,  
x 103u/L >11.1 –≤15.0  >15 - ≤ 20 >20.0  
WBC, decrease, cells, x 103u/L 2.5-<4.4 1.5-<2.5 <1.5 
Absolute Neutrophil Count  
(ANC), x 103u/L 1.2-<1.7 0.9-<1.2 <0.9 
Platelets, decrease, cells/mm3 124,000 -<134,000 100,000<124,000   <100,000   
Urine protein  Trace  1+ 2+ 
DMID Protocol 17-[ADDRESS_533989] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           107 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Appendix C: Vital Signs Adverse Event  Grading Scale  
Vital Signs Grading  
Adverse Event  Severity  Parameter  
Fever  1 38.0 – 38.4°C      100.4 – 101.1 °F 
 2 38.5 – 38.9°C      101.2 – 102.0 °F 
 3 >38.9°C             >102° F or ER visit or hospi[INVESTIGATOR_422710] (systolic)} 1 151-1 55 mm Hg  
2 156-160 mm Hg  
3 >160mm Hg or ER visit or hospi[INVESTIGATOR_422710]  (diastolic)  1 91 – 95 mm Hg  
2 96-100 mm Hg  
3 >100 mm Hg or ER visit or hospi[INVESTIGATOR_422711]  (systolic)  1 85-89 mm Hg  
2 80-84 mm Hg  
3 <80 mm Hg or ER visit or hospi[INVESTIGATOR_422712]*  1 45-50bpm *  
2 40-44 bpm 
3 <40 bpm or ER visit or hospi[INVESTIGATOR_284337]  1 101-115 bpm  
2 116-130 bpm  
3 >130 bpm or ER visit or hospi[INVESTIGATOR_059]  
* If subject baseline heart rate is < 45 beats per minute and the investigator determines that this is not 
clinically significant (e.g., athletes) and heart rate increases >4 5 beats per minute on moderate exercise 
(two flights of stairs), this will not be considered a grade [ADDRESS_533990] has significant 
abnormalities in their heart rate, they will be informed of the values and advised to seek care from their 
physician.  
}   If a subject has significant abnormalities in their blood pressure, they will be informed of the values and 
advised to seek care from their physician.  
 
  
DMID Protocol 17-[ADDRESS_533991] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           108 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Appendix D: Diarrhea/Vomiting Grading Scale 
Stool consistency  will be determined according to the  guide below:  
Stool 
Descriptor  Definitions  
Normal  Firm, tootsie roll consistency, soft pudding consistency  
Loose  Runny, takes the shape of the container, gravy consistency, brown liquid, 
opaque liquid, chocolate milk consistency 
Liquid/Watery  Clear liquid,  rice water, soapy water consistency  
 
All stools will be graded according to the Stool Grading Guide below:  
Clinical 
Feature  Grade 0  Grade 1  Grade 2  Grade 3  
Diarrhea  None In a 24/h period:  
 
3 loose stools or liquid stools  or  300-599 gm of 
loose or liquid stool In a 24/h period:  
 4-5 loose stools or liquid stools  
 or  600-800 gm of 
loose or liquid 
stool  In a 24/h period:  
 >6 liq
uid stools  
  or  >800 gm of 
loose or liquid 
stool 
Vomiting  None 1-2 epi[INVESTIGATOR_11630] 24 hours 3-5 epi[INVESTIGATOR_11630] 24 hours >5 epi[INVESTIGATOR_11630] 
24 hours 
Note: -2 loose or liquid stools or <300gm stool in a 24h period are not diarrhea,  
 
 
  
DMID Protocol 17-[ADDRESS_533992] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           109 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Appendix E: Solicited Adverse E vents Grading Scale 
Clinical Feature  Grade 0  Grade 1  
(mild)  Grade 2  
(moderate)  Grade 3  
(severe)  
Fever (oral 
temperature)  none  100.4 – 101.1°F 
(38.0 – 38.4°C)       101.2 – 
102.0°F 
(38.5 – 38.9°C)       >1020F (>38.9°C)            
or ER visit or 
hospi[INVESTIGATOR_422713]/or 
prevents daily activity 
Nausea  None  mild*  moderate**  severe***  
Abdominal 
Cramps /discomfort/
pain  none  mild*  moderate**  severe***  
Abdominal gurgling  none  mild*  moderate**  severe***  
Abdominal bloating  none  mild*  moderate**  severe***  
Myalgia  none  mild*  moderate**  severe***  
Malaise, fatigue  none  mild*  moderate**  severe***  
Anorexia, loss of 
appetite  none  mild*  moderate**  severe***  
Chills  none  mild*  moderate**  severe***  
 
Grading Scale  
0 = None 1 = *Mild , No interference with activity  
2 = **Moderate, Some interference with activity  
3 = ***Severe, Significant interference, prevents daily activity  
 
  
DMID Protocol 17-[ADDRESS_533993] 2022 
________________________________________________________________________________________________________ 
 
DMID/NIAID/NIH           110 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  Appendix F: Modified Vesikari Score 
Modified Vesikari Scale (17 Point Scale)  
Duration of Diarrhea (days)  Points  
1 1 
2-3 2 
≥4 3 
Maximum Number of Diarrheal Stools/ 24 hours   
3 1 
4-5 2 
≥6 3 
Duration of Vomiting (days)   
1 1 
2 2 
≥3 3 
Maximum Number of Vomiting Epi[INVESTIGATOR_1841]/ 24 hours   
0 0 
1 1 
2-4 2 
≥5 3 
Fever  (°C)  
≤37 0 
37.1-38.4 1 
38.5-38.9 2 
≥ 39 3 
Dehydration   
None  0 
IV Treatment  2 
 